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Alzheimer disease is characterized by the initial degeneration of a subset of 
cholinergic neurons. This pattern of degeneration can be triggered by overexpression of 
the amyloid precursor protein (APP) gene in humans. Interestingly, APP is widely 
expressed; it is therefore unclear why only certain cholinergic neurons are vulnerable to 
degeneration.  We show that widespread expression of the human APP gene in the 
nematode Caenorhabditis elegans also induces age-dependent apoptotic degeneration of 
select cholinergic neurons.  Identical results were obtained by overexpressing the 
orthologous worm gene apl-1. The pattern of neurodegeneration matched the cell-
autonomous accumulation of APP protein in vulnerable neurons and could be activated 
cell-non-autonomously by distinct portions of APP.  Vulnerability to APP accumulation 
and degeneration depended inversely on the level of ASK1/p38MAPK innate-immune 
signaling in cholinergic neurons.  Lastly, we identify a compound P7C3 that blocks 
entrance to apoptosis caused by APP or immunodeficiency.  Our results suggest that 
immunosenescence sculpts the cellular pattern of neurodegeneration by APP.  
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Chapter 1:  General Introduction 
 
Why Study Alzheimer’s Disease? 
 
Alzheimer’s disease is the most common form of dementia which leads to 
eventual death in all cases.  It was first described in 1906, and is characterized as a 
terminal progressive degenerative disorder.  Today, an estimated 5.4 million Americans 
suffer from Alzheimer’s disease (AD) (2012 Alz Facts and Figures); it is currently ranked 
as the sixth leading cause of death in the United States.  By 2030, a projected 66 million 
people worldwide will be living with dementia—a statistic set to rise to 115 million by 
2050 (Alzheimer’s Disease International Consortium, 2009).  For such a prevalent 
disease, the precise ethology of AD remains unclear.  There has been a large amount of 
time, money, and resources devoted to elucidating this mystery; but developing an 
effective treatment in the absence of understanding the true cause of the disease continues 
to be a major challenge.  As the elderly population battling this debilitating disease 
increases, it has left not only a burden on the patients themselves, but also a tremendous 
emotional burden on society.  The cost of care for a patient with AD is approximately 
$57,000 per year in the United States (Burns and Llife, 2009).   
It is, therefore, critically important to uncover the root cause of Alzheimer’s 
disease, not just the inevitable consequences, and to develop sufficient treatment and 
prevention strategies.  It has been difficult for researchers overcome the time and 
financial limitations of mouse models while still preserving disease relevance to the 
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human condition.  For example, many mouse models take 6 months to a year before 
showing any disease pathology, with many models only showing a small subset of 
phenotypes associated with Alzheimer’s disease.  This thesis sought to develop a 
physiologically relevant model of AD without these limitations and has successfully done 
so in the model organism Caenorhabditis elegans. 
 
 
What Exactly is Alzheimer’s Disease? 
 
 
AD can be divided into early-onset (younger than 65) and late-onset (older than 
65); both forms have a genetic component.  Early-onset AD (also known as familial 
Alzheimer’s Disease-FAD) accounts for 5-10% of all disease cases.  Early-onset AD 
generally becomes apparent in an individual’s mid-50’s and 60’s.  Based on genealogical 
and genetic studies, FAD is inherited as an autosomal dominant mutation in one of a 
handful of key genes; Amyloid Precursor Protein (APP), Presenilin 1(PSEN1), and 
Presenilin 2 (PSEN2) (Bertram and Tanzi, 2008).  Late-onset AD is considered to be a 
sporadic version, although there are a number of risk factors associated this form of 
disease.  The genetic and environmental causes of the sporadic form of the disease are 
very poorly understood.  Even though early-onset and familial AD account for only a 
small percentage of all cases, researchers have strived to understand the familial form in 
the hopes that it can help to elucidate some of the mystery behind the sporadic version of 
the disease.   
 3 
Two histological hallmarks of this disease are confirmed post-mortem, marked by 
the presence of extracellular amyloid plaques and intracellular neurofibrillary tangles.  
Until recently, this post-mortem affirmation made it difficult to diagnosis individuals 
exhibiting early signs of the disease.  The molecular mechanism(s) still have yet to be 
uncovered; therefore, it is yet unknown if the presence of plaques and tangles themselves 
serve a causative role in the pathology or a consequence of unidentified upstream 
culprits.  Mature plaques contain cleavage fragments of the Amyloid Precursor Protein 
(APP), mainly Aβ42 and Aβ40 (Iwatsubo et al, 1994).  These plaques are surrounded by 
activated microglia and astrocytes as well as inflammation-related proteins that may have 
negative consequences on the nearby cells (Eikenlenboom et al., 2002).   Neurofibrillary 
tangles are composed of hyperphosphorylated forms of microtubule-associated protein 
tau (MAPT).  These fibers are normally associated with maintaining cellular structure 
and transport via microtubules, but become unstable in tangle formation.  This results in a 
loss of cellular transport ability throughout the cells (Iqbal, 2005).  
A controversy exists as to which (or whether) these hallmarks might have a 
causative role in disease pathology.  Extensive research has been done looking into both 
APP and tau; the major consensus is that APP pathology is upstream of tau.  Using the 
model C. elegans, it is possible to address both APP and tau questions.  Strong orthologs 
exists for both mammalian genes in the worm.  This thesis has focused on the 
contribution of APP to Alzheimer’s disease in a developed AD model.  One future 
direction of the project will be to assess the contributions of tau, as well as the potential 
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interaction between APP and tau in this in vivo system that allows rapid genetic 
maniuplations.    
 
New Model for AD Research 
 
 
Some cases of AD are clearly linked to the amyloid precursor protein (APP).  
Individuals who carry an additional wild-type copy of the APP gene or have rare 
mutations in APP develop early-onset AD (Bertram and Tanzi, 2008).  For example, 
individuals with Down syndrome carry an addition copy of APP due to a triplication of 
the 21
st
 chromosome (which is where APP lies).  This then leads to the inevitable result 
of early-onset AD in DS patients (Ness et al., 2012).  Gain-of-function mutations in APP 
have also been shown to give rise to AD (Goate et al., 1991).  Conversely, a distinct APP 
mutation has recently been linked to lower incidence of AD in an Icelandic population 
(Jonsson et al., 2012).  Despite the certainty about the involvement of APP in AD, it 
remains unclear how a single extra wild-type copy of APP contributes to AD and how 
potential pharmacological intervention may prevent this neurodegeneration.  This idea 
was the central theme for research conducted in this thesis.  The goal was to generate an 
AD model in C. elegans that expressed this additional wild-type copy of APP (or the 
worm ortholog apl-1) to see if we could observe any physiologically relevant phenotypes 
associated with human AD.   The speed and low-cost to which this can be done is a very 
attractive alternative to generating new AD mouse models.  C. elegans also allows us to 
address questions that are not possible in other model systems.   
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Mouse Models of AD 
 
Multiple labs have developed transgenic mouse and invertebrate models of AD in 
which the APP gene is overexpressed (Ting et al., 2007; Calhoun et al., 1999; Sturchler-
Pierrat et al., 1997; Ghosal et al., 2009).  These models include both wild-type and 
mutated versions of the gene, as well as cleavage products of the mature APP protein.  
The models have proven to be important tools to study the progression of APP-induced 
neurodegeneration and to discover potential methods to slow or prevent damage.  For 
instance, in mice, overexpression of either APP or the Aβ peptide in mice recapitulates 
the formation of plaques and neurodegeneration of cholinergic neurons in adult-stage 
animals mirroring human AD (Small and Duff, 2008).  However, recent studies have 
found that medical treatments eliminating Aβ-rich plaques do not prevent the progression 
of neurodegeneration and death in humans (Howlet and Richardson, 2009).    
This raises the question of whether additional portions of APP, other than Aβ, 
might be more relevant to AD.  In addition, these models recapitulate some, but not all, of 
the pathological symptoms associated with AD. (Comprehensive Review- Chin, 2011)  
Unfortunately, the process of strain generation is expensive and slow in the mouse, 
severely limiting the number of hypotheses that can be tested in a timely fashion.  It often 
takes 6 months or more to begin to observe any of the traditional characteristics of AD, as 
well as many months more to analyze the progression of pathology in this system.  As the 
number of baby boomers continue to edge closer to the late-onset age for AD, an 




C. elegans as a model system for Alzheimer’s 
 
C. elegans as a model organism offers several advantages to study Alzheimer’s 
disease causes and consequences in the context of a whole animal.  It has a short life span 
(3 days to reach adulthood), making aging studies possible in very short time frames.  
Forward and reverse genetics are extremely facile in the worm, as is molecular 
manipulation of single genes and production of transgenic animals.  This allows 
researchers to easily test several gene hypotheses in parallel or in combination.  Every 
cell in the tiny (1mm) worm is identified, including the 302 neurons which compose its 
nervous system.  Furthermore, individual cells can be examined by microscopy in the 
living, transparent worm.  Hundreds of promoters have been characterized that allow the 
expression of genes in subpopulations of cells, enabling the marking of individual cells so 
they can be identified with fluorescence.  The ability to track individual cells in vivo 
throughout the life span of the worm non-invasively represents a huge advantage not 
previously available.  It is also possible to monitor hundreds of animals simultaneously, 
making large population studies in a variety of genetic backgrounds easily manageable.  
C. elegans has a number of discrete behaviors governed by distinct, and often 
independent, neural circuits.  The roles of particular neurons in these behaviors can be 
discerned by mutagenesis as well as by single cell ablation with a laser.  Approaches 
using C. elegans are tried and tested.  Because of the conservation of genes and cellular 
mechanisms during evolution, studies in C. elegans were the first to identify several vital 
pathways, including those involved in cell death and necrosis (Putcha and Jonhson, 
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2004).  C. elegans share 40% homology, 66% orthology, of genes with humans.  
Therefore, conclusions drawn from specific genes in this facile and expatiated system can 
lead to valuable conclusions relevant to their human gene counterparts.  
 
 Despite these advantages, previous attempts to produce a model of AD in 
C. elegans have been less productive, in large part due to the extreme phenotypes that 
result from the overexpression of multiple copies of APP.  For example, in contrast to the 
mouse model, multi-copy overexpression of the APP ortholog, apl-1, led to a collection 
of extreme phenotypes including partial lethality, arrested development, and extensive 
vacuolization (Hornsten et al., 2007).  I have also confirmed these findings by 
overexpressing multiple copies of the apl-1 gene and the APP gene with a pan-neuronal 
promoter.  Neurodegeneration could not be easily discerned in these animals.  Utilizing 
the MOSCI technique (Frokjaer-Jensen et al., 2008), which allows the insertion of a 
single gene into the C. elegans genome, it is now possible to determine if an extra single 
copy of the apl-1 or APP results in phenotypes that better reflect the human AD 
condition.  If so, it will then be possible to discern the molecular mechanism(s) by which 
these pathological phenotypes arise.  
An additional advantage of using a C. elegans disease model is the ability to 
conduct high-throughput drug screening in a short timeframe.  It is possible to screen 
through hundreds, even thousands, of potential drug candidates in just a few months.  
Positive hits can then be immediately tested in murine models of AD to determine if the 
beneficial effects are transferable to a mammalian system.  Mouse researchers have to be 
very selective about the drugs they test, based on the constraints of their system 
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mentioned above.  If we can streamline the candidate drug target process for them, it 
could expedite the timeframe to which a therapeutic drug could make it to the aging AD 
population in desperate need of a cure.    
This thesis proposed using the C. elegans system to investigate how apl-1 and 
APP overexpression lead to degeneration of specific neuron subclasses.  We will also test 
genetic and pharmacological strategies to prevent selective neuron loss.  This research 
has resulted in a model for which an additional wild-type copy of APP can lead to the 
neurodegeneration of a specific subset of neurons; the same neurons lost first in the 
human pathology.  Though this model cannot recapitulate certain aspects of the disease, 
including higher-order learning and specific brain region analysis, it does allow us to 
discern the molecular mechanism by which a select subset of neurons degenerate in this 
disease pathology.  Results obtained from this study can then yield powerful insights to 
potential parallels in the mammalian system not previously available in such a timely 
fashion.  This research has also lead to the identification of novel compounds that can 
prevent APP-induced neurodegeneration, as well as their potential location and 
mechanism of action.   
It would have taken vast amounts of time, money, and resources to conduct a 
fraction of this research in a mouse model; some experiments can only be done in a 
simper system like C. elegans.  This model can continue to be used in the future to 
explore other pathological hallmarks of AD not elucidated here; some of which include 
plaque formation, tau aggregation, and the spreading of neurodegeneration to other cell 
types in an aging animal.   
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APP and Alzheimer’s Disease 
APP is a single transmembrane-spanning protein with a large extracellular domain 
and a smaller intracellular domain (Figure 1; LaFerla, 2002).  It is expressed in many 
tissues, but in high prevalence at neuronal synapses.  The primary function of APP has 
yet to be determined, but roles have been supported in neuron growth, survival, and post 
injury repair (Priller et al., 2006; Turner et al., 2003).  This is based on increased 
expression levels during neuronal differentiation and after neuronal injury occurs.  Roles 
in cell signaling and adhesion have also been proposed, but the research is still limited 
(Zheng and Koo, 2006).  Structural analysis of the APP protein reveals a few potential 
function s (not mutually exclusive): as a receptor at the cell surface, fragments may be 
released at the cell surface that can act as signaling molecules, or the intracellular domain 
can be cleaved and influence transcription of downstream targets.  Because of the genetic 
link between APP and AD, much research has been put into how this protein is 
processed.  As a result, the cleavage process of APP into its many parts is much more 
understood than the actual endogenous function of these cleavage products or the 
pathogenic roles they may have.   
Mature APP undergoes a sequential cleavage by 3 or more proteases during post-
translational processing which lead to several cleavage products.  (Figure 1).  Initially, an 
α-secretase or β-secretase cleaves the extracellular domain from the membrane-anchored 
carboxy-terminal fragment.  After initial cleavage, a secondary δ-secretase cleaves within 
the membrane-spanning domain.  The major δ-secretases in humans are (PSEN1 and 
PSEN2 (mentioned earlier).  This generates an Aβ fragment and a released intracellular- 
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portion.  The α-cleavage pathway is the main pathway used under normal physiological 
conditions, while the proposed amyloidgenic pathway involves the β cleavage products.  








 Figure 1.  Proteolysis of APP.  APP is a single transmembrane protein that 
undergoes several proteolytic cleavages to produce multiple products.  α-
secretase cleavage is thought to be the non-amyloidgenic pathway, while the 
β-secretase cleavage produces potentially disease causing fragments.  
Illustration adapted from LaFerla, 2002.   
 
human brain (Meziane et al., 1998; Mattson, 1997).  Increased Aβ loads in patients with 
AD are accompanied by high levels of the secreted cleavage product of  β-secretase 
(sAPPβ) and the intracellular domain cleavage product (AICD).  One of the major modes 
of AD thinking is that the β cleavage process is somehow preferentially chosen in the 
disease state, leading to more toxic Aβ cleavage products (mainly Aβ42).  This is the 
main line of thinking behind the Amyloid Cascade Hypothesis, one competing theory for 
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the root cause of AD.  Using our model of AD in C. elegans, we are able to address the 
contributions of different portions or cleavage products of APP to disease pathology.  It 
was also possible to combine a subset of cleavage products in vivo to assess any potential 
synergistic effects. This is not easily accomplished in mouse models. 
 
Competing Theories in the Field   
Denoted as the Amyloid Cascade Hypothesis, amyloid deposition is thought to be 
the initiating step to which the remaining observed characteristics are a consequence.  
Downstream consequences include inflammation, tau hyperphosphorylation, and 
eventually neurodegeneration (Hardy, 2006).  Much of the drug development has been 
based on this view, yet none to date have proved to be effective in improving the care of 
these patients.   The goal of many of these drugs was to eliminate or neutralize plaques.  
This adds to the questions of whether the plaques themselves are destructive themselves 
or a consequence of upstream targets.   
An alternative hypothesis has emerged around the microtubule-associated protein 
Tau.  This view holds that tau abnormalities initiate the disease cascade (Mudher et al., 
2002).  Phosphorylated tau is a necessary physiological function to promote effective 
cellular transport along microtubules in the cell.  Pathology results when the tau becomes 
hyperphosphorylated, pairing with other tau fibers in the cell—producing intracellular 
neurofibrillary tangles (Goedert et al., 1991).  These tangles, in turn, lead to the 
disintegration of transport along microtubules in the cell, potentially leading to apoptosis. 
Deletion of tau was also shown to prevent many of the AD phenotypes in APP transgenic 
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mice (LeRoy et al., 2012).  The Tau Hypothesis lost momentum when a number of mouse 
models can exhibit AD like symptoms in the absence of tangles (Kitazawa et al., 2012; 
Lalonde et al., 2012).  Currently, most scientists agree that tau pathology is secondary to 
amyloid pathology. 
Technological advances in genome sequencing have yielded the identification of 
more than ten risk genes for late-onset disease (Hollingworth et al., 2011; Lambert et al., 
2009; Seshadri et al., 2010).  APOE4 remains the largest risk factor, but TREM2 has 
been getting a lot of attention recently.  TREM2 is a receptor located on myeloid cells 
that are triggered during an immune response.  It is believed that a mutation in TREM2 
prevents white blood cells from controlling the amount of Aβ present, conferring a 3-5 
times increased risk of contracting late-onset AD (Jonsson et al., 2013).  Identification of 
these additional risk factors has led to the investigation of other components contributing 
to the disease pathway; including lipid metabolism, the immune system, and synaptic 
functioning mechanisms.  
 
Molecular Basis for Cell Death in AD 
There is extensive neurodegeneration in the progression of AD.  The process by 
which these vulnerable cells die is poorly understood.  There are two main modes to 
which a cell can execute its demise:  the process of necrosis or apoptosis.  Necrosis is the 
type of cellular death normally associated with trauma, infections or toxins.  Not easily 
controlled, cell death products are often released into the extracellular space and can 
result in harm to the surrounding cells (Proskuryakov et al., 2003).  Alternatively, 
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apoptosis is thought to be a much more regulated “programmed” cell death process.  
Apoptosis follows a number of characteristic steps that allow dead cells to be engulfed 
before any harmful products can be released (Alberts et al., 2008).  This type of cell death 










 Figure 2.  Conservation of Apoptotic Machinery across Species.  A 
comparison between C. elegans and mammals shows conservation of key 
genes throughout evolution.  Illustration adapted from  herkules.oulu.fi. 
Both of these pathways have key gene players involved in the execution of their 
processes, a few of which have been assessed in mouse models of AD.  Caspase-3 is a  
protease that plays a central role in the execution phase of apoptosis (Figure 2).   Acting  
as an executioner, it can trigger cell death based on intrinsic or extrinsic cell signals.  It 
has been argued that there are activated caspases and apoptosis-like events in Alzheimer 
brains (Su et al., 2001).  This has been further supported by an enrichment of caspase-3 
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found in a synaptic fraction of Alzheimer brains (Louneva, 2008; Ribe et al., 2008).  
Conversely, treatment of a mouse model of AD with caspase inhibitors resulted in 
improved synaptic dysfunction, assessed by contextual fear conditioning (D’Amelio et 
al., 2011).   
These studies have only been able to correlate caspase activation and presence to 
AD pathology; there is still no direct evidence that the neurons in AD are dying through 
the process of apoptosis.  C. elegans has a very clear ortholog of mammalian caspase-3, 
denoted ced-3, in addition to other molecules conserved in apoptosis.  The Nobel Prize 
was awarded in 2002 to C. elegans researchers for their work on apoptosis and 
discoveries that paralleled in the mammalian system, further validating this model as 
physiologically relevant.  Using our C. elegans model of AD, we have been able to 
definitively show for the first time in any AD mutant model that APP can trigger cell 
death through apoptosis in vivo.   
 
Role of Innate Immune System in AD 
Aging is the leading risk factor for Alzheimer’s disease.  Aging is associated with 
increased mortality from infection in evolutionarily diverse species (Shanley et al., 2009).  
These observations have been attributed to an age-dependent decline in immune function, 
also known as immunosenescence.  It has been proposed that the immune system 
efficiency declines with aging, making these neurons more vulnerable to insults.  Could 
this be a “tipping point” for effective neurodegeneration in AD brains?  Immune 
activation and inflammation within the central nervous system is a classical feature of 
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neurodegenerative diseases.  It remains controversial as to whether immune activation is 
contributing to the neuronal damage or attempting to prevent damage in AD.  One 
hypothesis is that Aβ plaques and tangle stimulate a chronic inflammatory reaction to 
clear debris, but this chronic activation can eventually erode surrounding tissues (Town et 
al., 2005).    
As part of the innate immune system, microglia act to defend against pathogens 
and to clear injured neurons and debris.  Engulfment of these apoptotic cells is essential 
to prevent an inflammatory response (Napoli and Neumann, 2009).  It has also been 
shown, however, that microglia can promote inflammation, potentially exacerbating 
neurodegenerative diseases (Minghetti, 2005; Block et al., 2007).  TREM2 is a gene 
expressed in microglia and neurons that has received a lot of attention; its role in neurons 
remains to be studied.  Depletion of TREM2 amplifies inflammatory cytokine responses 
(Jonsson et al., 2012; Guerreiro et al., 2012), while treatment with TREM-2 expressing 
cells can reduce inflammation and improve disease pathology in a mouse model 
(Takahashi, 2010).  Together, these results demonstrate a critical role for immune 
signaling and inflammation in degenerative pathology.   
Clinical pharmaceutical trials aimed at modulating the immune system in AD 
have largely focused on either dampening down central proinflammatory innate 
immunity axis or manipulating adaptive immunity to facilitate the removal of centrally 
deposited beta amyloid.  One immune-modulatory strategy in AD was centered on a 
vaccination against Aβ in an attempt to reduce plaque burden.  The hope was that a 
decreased plaque load would result in cognitive recovery, or at least halt further decline.  
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The initial studies in mouse models demonstrated decreased protein aggregation and 
improved cognitive signs (Yamada et al., 2009).  This approach in human clinical trials 
proved disappointing.  Antibodies did reduce plaque aggregation in patients but did not 
result in improved cognitive function. (Holmes et al., 2008).  It is unclear if treatment of 
patients before plaque deposition would have had positive effects.  Collectively, current 
research demonstrates that alterations in the immune system can contribute to the disease 
pathology of AD.  If the molecular basis of increased APP can be elucidated, it might 
lead to the development of novel and effective therapeutic targets.   
Most of the genes involved in the innate immune signaling cascade are conserved 
in C. elegans.  This allows us to address the possible roles of many of the immunity 
genes in a timely manner using our model of AD.  We can address the consequences of 
increasing or decreasing single immunity genes in vivo, as well as manipulating many 
pathway components simultaneously.  The speed of this model lends itself to quick 
epigenetic analysis, pinpointing exactly where overexpression of APP and the immune 
system come together and contribute to disease pathology.  We have shown that boosting 
a conserved innate immune signaling axis can lower APP-induced neurodegeneration in 
or model of AD, while lowering immune signaling can promote degeneration even in a 
wild-type background. 
 
Cell-type Specific Degeneration 
It was originally thought that AD was induced by reduced synthesis of the 
neurotransmitter acetylcholine in the brain; this is the oldest known hypothesis of AD 
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causation.  It is known that the cholinergic neurons are the first do die in the disease 
progression of AD, though it is not known why these cells are particularly vulnerable.  
Selective vulnerability is not exclusive to AD; many other neurodegenerative diseases 
target a specific subset of neurons first ranging from ALS to Parkinson’s disease (Boillee 
et al., 2006; Davie, 2008; Estrada et al., 2008).    The model of AD proposed in this 
research demonstrates selective degeneration of a subset of cholinergic neurons, similar 
to that in the human condition.   
Most of the current AD drug therapies are aimed at increasing cholinergic neuron 
health and signaling.  Four major acetylcholinesterase inhibitors are currently on the 
market—tacrine, rivastigmine, galantamine, and donezeile (Pohanka, 2011).  
Unfortunately, none of these drugs have been shown effective in delaying the onset of the 
diseases.  If we can delineate what makes cholinergic neurons the initial target of this 
disease, we can begin to develop preventative strategies instead of ineffective coping 
strategies.  Using C. elegans as a model can exacerbate this process and get valid answers 
in a fraction of the time it would take in mouse models.   
 
Conclusion 
 This thesis will show demonstrate that a simple genetic system like C. elegans can 
be utilized to address large scientific questions.  Here, we show that a single additional 
copy of APP is sufficient to induce a select pattern of degeneration during middle age, 
mimicking the human condition.  We have also begun to elucidate the molecular 
mechanism by which this cellular death occurs.  Finally, we also reveal novel compounds 
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that can alleviate select degeneration in this model, paving the way for future drug targets 







Chapter 2:  Induction and Prevention of Patterned        




Alzheimer disease is characterized by the initial degeneration of a subset of 
cholinergic neurons. This pattern of degeneration can be triggered by overexpression of 
the amyloid precursor protein (APP) gene in humans. Interestingly, APP is widely 
expressed; it is therefore unclear why only certain cholinergic neurons are vulnerable to 
degeneration.  We show that widespread expression of the human APP gene in the 
nematode Caenorhabditis elegans also induces age-dependent apoptotic degeneration of 
select cholinergic neurons.  Identical results were obtained by overexpressing the 
orthologous worm gene apl-1. The pattern of neurodegeneration matched the cell-
autonomous accumulation of APP protein in vulnerable neurons and could be activated 
cell non-autonomously by distinct portions of APP.  Vulnerability to APP accumulation 
and degeneration depended inversely on the level of ASK1/p38MAPK innate-immune 
signaling in cholinergic neurons.  Lastly, we identify a compound P7C3 that blocks 
entrance to apoptosis caused by APP or immunodeficiency.  Our results suggest that 




Alzheimer’s disease (AD) is the most common cause of dementia and the sixth 
leading cause of death in the US, but the precise etiology of AD is unclear (Herbert et al., 
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2003).  Some cases of AD are clearly linked to the amyloid precursor protein (APP).  For 
instance, rare mutations in APP have been linked to familial cases of early onset AD 
(Bertram et al., 2008; Small et al., 2008) and a distinct APP mutation has been recently 
connected to lower incidence of AD in people from Iceland (Jonsson et al., 2012).  More 
commonly, individuals that carry additional wild-type copies of the APP gene, including 
those with Down syndrome, also develop AD (Zigman et al., 2007).  Conversely, 
individuals with Down syndrome that reach advanced age without signs of dementia have 
been shown to be disomic for APP (Prasher et al., 1998).  Consistent with these findings, 
overexpression of a wild-type (WT) copy of APP in mouse causes neurodegeneration 
(Simon et al., 2009), and a mouse model of Down syndrome that was made disomic for 
APP did not display AD-type symptoms (Salehi et al., 2006).  APP encodes a 
transmembrane protein that is enzymatically cleaved into several peptides, including Aβ 
peptides (Zhang et al., 2012).  Different variants of Aβ compose amyloid plaques found 
in the brains of AD patients and produce neurodegeneration and/or neural dysfunction in 
multiple model systems (Huang et al, 2012).  Despite this certainty about the involvement 
of APP in AD, it remains uncertain how only a single extra wild-type copy of APP 
contributes to AD and how pharmacological treatments may prevent this 
neurodegeneration.  
One of the most mysterious aspects of AD is that the first group of neurons to die 
includes a specific subset of cholinergic neurons important for memory (Davies et al., 
1976).  This initially limited pattern of degeneration is puzzling because the APP gene is 
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widely expressed throughout the brain (even in non-neural tissue (Neve et al., 1998)).  
Also perplexing, risk factors such as genetic allele status (e.g. APOE and TREM2) and 
medical history (e.g. chronic infection) increase the incidence as well as hasten the onset 
and progression of this pattern of degeneration without obviously targeting these 
cholinergic neurons (Kim et al., 2009; Honjo et al., 2009; Hamerman et al, 2006; 
Takahashi et al., 2007).  While progress has been made on theories to explain the 
progressive spread of degeneration throughout the brain (e.g. trans-synaptic spread of 
hyperphosphorylated TAU protein (De Calignon et al., 2012; Liu et al., 2012) and 
nonfibril Aβ (Nath et al., 2012)), fewer theories have been advanced to explain why 
certain cholinergic neurons are the first to degenerate, and why they only begin to 
degenerate in middle age (Saxena and Caroni, 2011; Benilova et al., 2012; Gotz et al., 
2009).   
Experimental study of the initial pattern of degeneration in AD can be difficult in 
rodent models of AD and humans due to the ambiguity of onset.  Salient behavioral 
phenotypes that correlate with initial degeneration are often absent and non-invasive 
methods to detect degeneration in vivo cannot provide insight until substantial portions of 
the brain have deteriorated (Ashe et al., 2010; Iqbal and Grundke-Iqbal, 2011).  To 
overcome certain limitations of rodent models, some have turned to simpler in vivo 
models, including the genetic model nematode Caenorhabditis elegans, to study aspects 
of AD (Hornsten et al., 2007; Link et al., 2003).  Studying the molecular origin of 
patterned neurodegeneration may be easier in C. elegans because it offers more rapid 
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genetic manipulation, a transparent body to visualize its completely described nervous 
system, and an easier way to link behavioral dysfunction to identified neurons.  
C. elegans models of AD have been limited, however, because until now they have not 
yet demonstrated neurodegeneration (Wentzell et al., 2010).   
Here, we describe the first example of a C. elegans model of AD that displays 
age-dependent patterned cholinergic degeneration upon expression of a single copy of 
human APP gene. We propose a novel mechanism to explain how the widely-expressed 
APP protein destroys a select subset of cholinergic neurons in middle age through cell-
autonomous selective APP accumulation, cell-non-autonomous signaling by distinct 
portions of APP, and decline in innate immunity. Additionally, we present the 
neuroprotective effects of a newly characterized compound, P7C3, which prevents APP-
induced neurodegeneration by blocking entrance to apoptosis. By combining the use of 
pharmacologically active agents with genetic manipulation of the nematode, we have 
attempted to dissect the molecular mechanism of patterned neurodegeneration found in 
AD. 
Materials and Methods 
Strains: Nemotode (C. elegans; Bristol strain N2 as wild type) strains were grown at 
20°C as described on 1.7% agar plates containing nematode growth medium and seeded 
with Escherichia coli strain OP50 (Brenner et al., 1974).  Animals cultured on plates 
contaminated with fungi or other bacteria were excluded from this study. The genotypes 
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of mutant and transgenic strains generated for this study were confirmed through PCR 
and/or sequencing and are listed with other strains used in Table 1.  
 









vxEx1[Prab3::apl-1::unc-54UTR, Cb-unc-119 (+)]; unc-119(ed3) 
III. 




vxSi50[Cb-unc-119 (+)] II.  (designated WT for this paper) 
5 JPS26 vsIs13 IV; egl-1(n4065) V; lin-15b(n765) X. 
6 
JPS27 






119 (ed3) III. 









vxEx39[Prab3:huAPP695:unc54UTR, Cb-unc-119 (+)], unc-
119(ed3)III. 
11 JPS40 vxSi35 II; unc-119 III; vsIs13 IV; lin-15B(n765) X. 
12 JPS57 ced-6(tm1826) III; vsIs 13IV; lin-15B(n765) X. 
13 JPS66 ced-3(ok734), vsIs13 IV; lin-15B (n765) X. 
14 JPS67 vsIs38 II; unc-119(ed3) III; vsIs13 IV; lin-15B(n765) X. 
15 JPS70 vsIs13 IV; crt-1(ok948), lin-15B(n765) V. 
16 
JPS71 
vsSi 1 II; ced-6(tm1826), unc-119(ed3)  III; vsIs 13IV; lin-15B(n765) 
X. 
17 JPS75 vxSi1 II; unc-119(ed3) III; vsIs13 IV; crt-1(ok948), lin-15B(n765) V. 
18 
JPS98 





unc-119(ed3) III ; vxSi38 IV. 
20 JPS113 unc-119(ed3) III; vsIs13, vxSi1 IV; lin-15b(n765) X. 
21 JPS114 vxSi II; unc-119(ed3) III; vs48[unc-17::GFP] 
22 JPS115 vsIs13 IV; egl-1(ok1418) V; lin-15b(n765) X. 
23 
JPS116 
vxSi1 II; unc-119(ed3) III; vsIs13 IV; egl-1(ok1418) V; lin-
15b(n765) X. 
Table 1.  Strains Generated and Utilized in This Study  
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Unc-119(ed3) III; vxSi1 IV. 









unc-119(ed3) III ; vxSi1 IV. 
27 
JPS145 
vxSi [Papl-1:apl-1:unc54UTR, Cbunc-119 (+)] II; unc-119(ed3) III; 




vxSi [Papl-1:apl-1:unc54UTR, Cbunc-119 (+)] II; unc-119(ed3) III. 
29 
JPS150 





vxEx151[Prab3::mCherry]; vxSi1 II; unc-119(ed3) III; vsIs13 IV; 
lin-15b(n765) X.  
31 
JPS152 
vxEx151[Prab3::mCherry]; vxSi38 II; unc-119(ed3) III; vsIs13 IV; 
lin-15b(n765) X.  
32 JPS166 VxSi1 II, juIOs76 II; unc-71(ju156), unc-119(ed3) III. 
33 
JPS167 





vxSi175[Prab3::huAPPC59::unc-54UTR, Cb-unc-119 (+)] II; unc-



















unc-119(ed3) III; vxSi 203[Prab3:huAPP695C59:unc-54UTR, cb-
unc-119(+)] IV. 
39 JPS 204 unc-119(ed3) III; vxSi203,vsIs13 IV; lin-15b(n765) X. 
40 JPS 205 vxSi176 II; unc-119(ed3); vxSi203, vsIs13 IV; lin-15b(n765) X. 
41 
JPS 206 
vxSi176 II; unc-119(ed3) III; vsIs13 IV; egl-1(n1418), lin-15b(n765) 
X. 
42 JSP 211 nsy-1(ok593) II; vsIs13 IV; lin-15b(n765) X. 
43 JPS 212 nsy-1(ok593), vxSi II; vsIs13 IV; lin-15b(n765) X. 
44 JPS 227 nsy-1(eg681) II; vsIs13 IV; lin-15b(n765) X. 
45 JPS 228 nsy-1(eg681), vxSi128 II; vsIs13 IV; lin-15b(n765) X. 
46 JPS 229 nsy-1(ok593), vxSi II; vsIs13 IV; egl-1(n4065), lin-15b(n765) X. 
47 JPS 230 acEx102; pmk-1(km25), vsIs13 IV; lin-15b(n765) X. 
48 JPS 231 vsIs13 IV; sek-1(km4), lin-15b(n765) X. 
49 JPS 232 tir-1(qd4) III; vsIs13 IV; lin-15b(n765) X. 










52 JPS305 vxSi291II; unc-119(ed3) III; vsIs13 IV; lin-15b(n765) X. 
53 JPS306 vxSi304II; unc-119(ed3) III; vsIs13 IV; lin-15b(n765) X. 
54 
JPS307 




vxEx308[Prab3::huAPP695L10stop::unc-54UTR, PCFJ90]; vsIs13 
IV; lin-15b(n765) X. 
56 
JPS309 








VxEx452[Punc-17::nsy-1(+), PCFJ90]; VxSi291 II; unc-119(ed3) 
III; VsIs13 IV; lin-15b(n765) X. 
59 
JPS453 
VxEx453[Punc-17::nsy-1(+), PCFJ90]; VxSi128 II; unc-119(ed3) 
III; VsIs13 IV; lin-15b(n765) X. 
60 
JPS454 
VxSi454[Prab3:huAPPC59:mcherry,unc-54UTR, cb-unc-119(+)] II; 
unc-119(ed3) III. 




II; unc-119(ed3) III. 
63 JPS457 VxSi456 II; unc-119(ed3) III; VsIs13 IV; lin-15b(n765) X. 
64 LX929 vsIs48[unc-17::GFP] 
65 EG1285 lin-15b(n765) X; oxIs12 [unc-47p::GFP + lin-15(+)] 
66 OH7235 zdIs13[tph-1::GFP] 
67 LX959 vsIs13 IV; lin-15b(n765) X. 
68 MT2236 egl-1(n4065) 
69 RB1021 crt-1(ok948) 
70 RB1305 egl-1(1418) 
71 RB885 ced-3(ok734) 
72 FX01826 ced-6(tm1826) 
73 CZ1931 juIs76 II; unc-71(ju156) III. 
74 EG4322 ttTi5605 II; unc-119(ed3) III. 
75 EG5003 unc-119(ed3) III; cxTi10882 IV. 
76 KU25 pmk-1(km25) IV; acEx102. 
77 KU4 sek-1(km4 
78 ZD101 tir-1(qd4) 
79 VC90 nsy-1(ok593) 
80 BZ981 nsy-1(eg691) 
81 CB408 unc-43(e408) 
82 MT1092 unc-43(n498) 
Table 1.  Strains Generated and Utilized in This Study (cont.) 
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Transgenesis:  Transgenic animals with a single copy of pan-neuronal apl-1, huAPP695 
full length, huAPP695N363 extracellular/transmembrane region, or huAPP695C59 
intracellular region were generated through the MOSSCI technique as previously 
described (Frokjaer-Jensen et al., 2008).  Briefly, we used Gateway technology 
(Invitrogen) to construct a vector with the apl-1(genomic) or huAPP695(cDNA) gene 
driven by the pan-neuronal promoter (Prab-3) and an unc-54 UTR adjacent to the 
Cb_unc-119(+) positive selection marker.  Transgenes were flanked by Mos1 transposon 





chromosome.  unc-119 mutant worms with specific Mos1 insertions sites were then 
injected with DNA.  Selection of mobile, non-fluorescent progeny led us to identify 
single-copy insertion animals.  Full insertion of the apl-1 or APP was confirmed by PCR 
and sequencing across the full transposon insertion site.  Strains were then termed 
SC_apl-1, SC_APP, SC_APPC59 and SC_APPN636  to signify a single gene copy 
insertion.  A control strain (designated WT for this paper) was also generated that 
contained only a single inserted copy of the Cb_unc-119(+) positive selection 
marker.  Transgenic animals with SC_apl-1 or SC_APP genes tagged with mCherry were 
generated as above with the mCherry cDNA sequence fused in frame to APP or apl-1 
before the unc-54 UTR to tag the C-terminal of the protein product. An additional strain 
using MOSSCI to integrate a single copy of mCherry cDNA driven by Prab-3 with unc-
54 3’ UTR was also generated (SC_mCh).  The full sequence of the inserted mCherry 
gene was confirmed by sequencing of genomic DNA.  Transgenic animals with multiple 
copies of pan-neuronal apl-1 or APP were also generated through injection (MC_APP 
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and MC_apl-1 respectively).  These multi-copy strains displayed a high level of lethality 
and developmental defects consistent with a previous report (Hornsten et al., 2007).  
DNA (25-50ng) vectors described above were injected into unc-119 mutant animals with 
fluorescent markers only.  Formation of an extra-chromosomal array containing multiple 
gene copies was confirmed in mobile progeny that retained fluorescent 
markers.  Expression level of unique sequence common to both APP and apl-1 genes was 
determined using real time (RT)-PCR with primers forward 
AAGCAGTGCAAGACCCAT and reverse TCATCATCGTCCTCATCATCA.  
 
Quantification of Neurodegeneration:  All analyses were completed with the 
experimenter blind to genotype and drug treatment.  Age-synchronized animals were 
immobilized on 2% agar pads containing 0.7 mM sodium azide.  Neurons that had dimly-
lit somas with missing/broken projections, abnormally shaped somas, or absent GFP 
labeling in the appropriate neuronal location were classified as 
degenerating.  GABAergic neurons were visualized with Punc-47p::gfp (strain EG1285), 
VA and VB cholinergic neurons with Punc-17::gfp (LX929); serotonin neurons included 
NSM, ADF, AIM, RIH, HSN class members which were visualized with Ptph-1::gfp 
(strain OH7235).  All animals were evaluated within 10 minutes of azide treatment.  In 
cases where the worm strains were too defective in egg laying to reach day 3 or 5 adult 
stage, the animals were treated at L4-larval stage onward with the sterilization drug 5-
fluoro-2’-deoxyuridne (FUDR, 0.12mM final) (Sigma).  We found that this drug had no 
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effect on the progression of degeneration of VC neurons (e.g. compare untreated animals 
in Figure 2D to FUDR-treated animals in Figure 6B).  The percentage of VC4 and VC5 
neurons that succumbed to APP-induced degeneration was compared for different groups 
(strain, age, drug condition) using planned Fisher’s exact tests (Zar et al., 1999).   
Protein Localization Analysis: Day-1, -3, and -5 adult mCherry-tagged APP and APL- 1 
strains were immobilized on 10% agarose pads containing microbeads (Fang-Yen et al., 
2012). Animals expressing GFP/mCherry-tagged transgenes were observed under a Leica 
laser scanning confocal microscope (Leica TCS SP5 II) with a 63x oilimmersion 
objective (numerical aperture: 1.4). When two channels were used, images are acquired 
sequentially with the pinhole diameter set to 1.2 Airy units. Z-stacks were then taken at 
40x magnification under red and green fluorescence separately, then pooled together to 
visualize co-localization with ImagePro Plus (Mediacybernetics). For comparison of 
fluorescence intensities in different areas of the worm, images were acquired under an 
identical exposure time, gain and pinhole diameter. Quantitative comparison of mCherry-
tagged APP accumulation in VC neurons was performed by measuring average intensity 
of red mCherry signal versus green gfp signal in select areas of interest using ImagePro 
(Media Cybernetics) and compared with a t-test. 
 
 
Laser Ablation of Neurons: Neurons were ablated as previously described (Fang- Yen et 
al., 2012). VC neurons were visualized using an integrated fluorescent strain, in which 
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VC neurons are labeled with GFP (strain LX959). All ablations were compared with 
shams of the same genetic background in which a laser was shot next to the animal.  
 
 
Pharmacology: Drugs were freshly prepared in buffer (M9) solution and pipetted onto 
small seeded plates. These plates were allowed to dry at least 2 hours at room 
temperature before use. The final drug concentrations of solid media are: Dimebon, 50 
μM (Tocris); P7C3, 50 μM (generous gift from Drs. Pieper, Ready and McKnight, 
UTSW). All other chemicals used in this study were at a concentration of 50μM unless 
specifically stated otherwise.  Well-fed larval stage 4 animals were picked onto seeded 
plates containing .12mM FUDR with or without drug. Animals were then allowed to age 
at 20°C for ~20 (day 1 adult), ~68 (day 3 adult) and ~116 hours (day 5 adult) before 
analysis. Controls using buffer with no drug were performed on each strain for each 
assay, and each assay was repeated multiple (3-8) times. Data were then averaged and 
statistically compared with planned non-parametric Χ2 analyses (Zar, 1999). 
 
 
Percent Lethality: The number of eggs laid by 10 first-day adult worms on bacterial 
plates (OP50) over 3 hours was counted, and surviving adult-stage progeny were then 
counted 72 hours later. Assays were repeated across 3 plates at least 3 times and 
percentages that failed to survive to adulthood were averaged. 
 
 
Egg-retention Assay: Plates of non-starved adult worms were bleached to yield a 
synchronized population of eggs. Eggs were allowed to develop for ~55 hours (day 1 
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adult) and ~103 (day 3 adult) hours at 20°C. Animals were then individually dissolved in 
1M NaOH in individual wells of a 96-well plate, and eggs retained within the dissolved 
adult animal were counted. 
 
 
Swimming Kinematics: Worms were submerged in NGM liquid and recorded for 1 
minute following a 2-minute acclimation period. Spine analysis software was then used 
to calculate and plot the midbody angle of the worm as previously described (Pierce- 
Shimomura et al., 2008). Head-bend frequency was determined based on the average 
time it took an animal to make 20 complete-cycle head bends. Defective swimming of 
single-copy APP or apl-1 strains could not be simply explained by accumulated eggs 
restricting motion because animals sterilized with 5-fluoro-2’-deoxyuridne (0.12mM  
final) (Sigma) displayed the same defect. 
 
Statistics: Unless indicated otherwise, averages are stated as mean ± SEM. 
 
Results 
Pan-neuronal overexpression of APP induces age-related degeneration of a specific 
subset of cholinergic neurons 
Both human  APP and nematode ortholog apl-1 genes are widely expressed 
throughout the nervous system as well as in non-neuronal tissues (Bertram et al., 2008; 
Link et al., 2003).  To focus on the nervous system, we generated strains that used a pan-
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neuronal promoter (Prab-3) to express a single wild-type copy of human neuronal APP, 
or an extra single copy of apl-1, knocked into a specific locus on the second 
chromosome.  These transgenic strains are designated SC_APP and SC_apl-1 strains 
respectively.  Both strains appeared normal in morphology and development from egg to 
young adult, and displayed an expected 2-fold higher expression of sequence common to 






 Figure 1.  Quantification of APP and apl-1 expression. (A) mRNA 
expression levels of sequence shared with apl-1 and APP are about 2-fold 
higher in SC_ overexpression strains compared to WT. Strains that express 
multiple copies (MC) of APP or apl-1 show even higher levels of 
expression. Primers used were common to both APP and apl-1 sequences 
(see methods). (B) Quantification of VC 4&5 degeneration shows 
indistinguishable pattern of degeneration for SC_apl-1 and SC_APP strains 
generated on different chromosomes (II and IV) under control of pan-
neuronal promoter (Prab-3) or using endogenous promoter Papl-1 (n>124 
neurons, 62 animals per bar). All day-3 and day-5 data are significantly 
higher than a “wild-type” strain (LX959) that expresses GFP in VC neurons 



























































































































 Figure 2. APP induces age-related degeneration of a specific subset of 
cholinergic neurons in C. elegans.  (A) Time course to middle age. (B) All 
six VC neurons visualized with GFP with animal outlined in pink.  (C) 
Same individuals on adult days 1 and 3. VC4&5 neurons selectively 
degenerate in a strain that expresses a single copy of APP (SC_APP).  
Remnant GFP, green arrows. Cartoon depictions for day 3 adult below.  (D) 
Quantification of percentage degeneration of different neuronal classes.  
VC4&5 selectively degenerated in SC_apl-1 and SC_APP strains. Planned 
Fisher’s exact tests compare vs same age WT where * P<0.003, ** 
P<0.00001, n>124 neurons (62 animals) per bar.  
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We noticed, however, that SC_APP and SC_apl-1 worms displayed an abnormal 
hinging motion at the midbody during swimming on the third day of adulthood.  This 
corresponds to post-reproductive peak and thus is considered “middle age” for C. elegans 
(Figure 2A) (Tartar et al., 2010).  Coincident with this phenotype, we observed one or 
more small vacuoles at the midbody that were suggestive of neurodegeneration (Figure 
4A, inset shows Nomarski image of dying neuron identified by position as cholinergic 
neuron VC5). This prompted us to investigate the health of neurons more easily by 
crossing in fluorescent reporters to label distinct classes of neurons.  We discovered that 
the VC-class cholinergic (ACh) neurons were often absent or dying in the SC_APP and 
SC_apl-1 strains in middle-aged adults.  Out of the six VC neurons, the VC4 and VC5 






 Figure 3. Incidence of degeneration of VC cholinergic neurons. Although all 
six of the VC-class cholinergic neurons show age-related progression of 
degeneration, neurons VC4 and VC5 show the highest incidence of 
degeneration. n>124 neurons, 62 animals per bar. 
 




















Thus, for convenience, we confined further analyses of VC-class neurons to these two 
neurons.  Compared to a control “wild-type” strain (see methods), our AD model strains 
had a significant percentage of VC4&5 neurons that degenerated by the first-day (~10%) 
and third-day (30–40%) of adulthood (Figure 2D). After inspecting individual neurons 
from different classes, including those that are adjacent to the VC neurons and others 
throughout the ventral nerve cord appeared healthy in appearance in our AD model 
strains (Figure 2D). These included all 25 GABAergic neurons in the worm nervous 
system, as well as the 24 VA- and VB-class cholinergic neurons in the nerve cord. 
Likewise, nine serotoninergic (5HT) neurons appeared normal in our AD models (Figure 
2D).  Thus, after direct inspection of 64 of the 302 neurons that compose the C. elegans 
nervous system (White et al., 1986), we find that the six VC-class cholinergic neurons are 
particularly vulnerable to APP-induced degeneration.   
Human AD is associated with an age-related decline in memory and cognition 
behaviors that depends on proper function of a vulnerable subset of cholinergic neurons 
(Davies et al., 1976; Bowen et al., 1976; Perry et al., 1977).  Although C. elegans does 
not possess sophisticated forms of memory comparable to humans, we found that our AD 
models displayed a decline in simple behaviors with age.  We focused on two behaviors: 
egg laying and swimming, which depend, in part, on the VC neurons and many other 
neurons (Zhang et al., 2008; Vidal-Gadea et al., 2011).  SC_APP and SC_apl-1 strains 
retained a normal number of eggs in first-day adults, but retained significantly more eggs 
than wild-type and a control strain (designated WT for this paper, see methods) in third- 
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 Figure 4. APP induces age-related decline of behaviors that depend on 
specific cholinergic neurons that degenerate.  (A,B) Overexpression strains 
retain significantly more eggs in middle age compared to WT. (A) 
Normarski photomicrographs of eggs (yellow arrows) retained in the 
midbody of adults. Solid arrow indicated vacuole indicative of 
neurodegeneration with Nomarski optics; double arrow indicates vulva. 
Inset shows magnified view. Quantification of egg retention (B) and 
midbody curvature time course (C).  Deficits are recapitulated with laser 
ablation of VC4&5 neurons.   For statistical comparisons of egg retention, 
n>48 animals per bar, planned t-tests vs same age WT (or ablated vs sham) 
where **, P<0.001 and *, P<0.05.  Error bars, s.e.m.  
 
 





































































 Figure 5. APP overexpression produces same effects regardless of 
chromosomal insertion site and promoter. (A,B) Egg-retention defects were 
Supplemental Text new 2 similar in SC_apl-1 and SC_APP strains 
generated on different chromosomes (II or IV) with pan-neural promoter 
(Prab-3), using the endogenous apl-1 promoter, or after laser ablation of 
VC4&5 neurons in a LX959 background (data same as in Figure 2) (n>48 
per bar). Asterisks denote significant difference from WT in (A) and from 
same condition dead vs alive.(B). (C) Deficits in head-bend frequency of 
SC_apl-1 and SC_APP swimming correlates with VC4&5 death, 
irrespective of chromosome integration site (n>20 per bar). For all panels, 
statistically compared with planned t-tests vs same age WT where *, P<0.01, 
expect for ablated animals which were compared to same age sham animals 
















































































































































































Day 3 VC4&5 alive
Day 3 VC4&5 dead
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day adults (yellow arrows in Figure 4A,B; Figure 5A).  Likewise, our AD models 
exhibited defective swimming in third-day but not first-day adults.  Frequencies of head-
bending were slightly decreased (Figure 5C) and bends at the midbody were even slower 
and biased towards the ventral side (Figure 4C).  The pattern of degeneration and unique 
behavioral defects could be not explained by a non-specific effect of the chromosomal 
integration site because integration of these genes into a different locus yielded identical 
results (Figure 1B; Figure 5A,C).  Nor could it be explained by the particular Prab-3 pan-
neuronal promoter because we also observed the same pattern of degeneration and 
behavioral defects when using the endogenous apl-1 promoter that expresses throughout 
the nervous system and additional tissues (Figure 1B; 5A,C).   
Further experiments with laser ablation revealed that the age-related decline in 
behaviors could be primarily explained by the death of the VC4 and VC5 cholinergic 
neurons.  Ablation of VC4&5 in a WT background caused retention of a modest but 
significant number of eggs in first-day adults, and even more eggs in third-day adults 
(Figure 4B; Figure 5A).  Another striking effect of APP and apl-1 overexpression is 
ventral-hinged swimming where over 80% of the single swim-cycle lags on the ventral 
side.  Ablation of VC4&5 neurons recapitulated this unique phenotype and decreased 
head-bend frequency during swimming (Figure 4C; Figure 5C).  Behavioral defects 
appeared to be due to the death of VC neurons because there was a perfect correlation 
between individuals with behavioral defects and those with degeneration of VC4&5 
neurons in WT and AD model strains (Figure 5B,C).  
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Distinct portions of APP induce identical pattern of neurodegeneration 
The C. elegans APL-1 protein is highly homologous to human APP in several 
regions, especially in the intracellular portion (Figure 6A). The remaining portion with 
transmembrane and extracellular regions is less well conserved, and notably lacks 
homology with Aβ
 
(Daigle et al., 1993). This suggested to us that the intracellular portion 
may be more important to produce neurodegeneration in C. elegans. We tested if pan-
neuronal expression of a single copy of only the conserved intracellular portion of APP 
(C59) produced neurodegeneration with a new transgenic strain SC_APPC59. We found 
that it was sufficient to recapitulate the same pattern of degeneration and behavioral 
defects observed in the SC_APP strain that expressed full-length human APP (Figure 6B-
D).  We next tested whether a single copy of the remaining combined extracellular and 
transmembrane portion (N636) produced degeneration with an additional transgenic 
strain SC_APPN636.  This strain also showed VC4&5 neurodegeneration and associated 
VC4&5-dependent behavioral defects (Figure 6B,C).  Together, these additional 
transgenic strains demonstrate that distinct portions of wild-type human APP protein 







RRRR- - - AMRGFI EVD- VYTPEERHVAGMQVNGYENPTYSFFDSKA 
KKKQYTSI HHGVVEVDAAVTPEERHLSKMQQNGYENPTYKFFEQMQN 
: : : :      : * . : * * *  .  * * * * * * : :  * *  * * * * * * * * . * * : .   
C.  el egans APL- 1 
Human APP 
54% identity, 83% similarity 
Conservation of intracellular domain 
I dent i cal  r esi dues *  
Conser ved r esi dues :  




























 Figure 6. Distinct portions of APP are sufficient to induce identical pattern 
of cholinergic degeneration.  (A) ClustalW alignment shows high 
conservation of intracellular domain of human APP with the equivalent 
portion of C. elegans APL-1 protein. (B) Quantification of percent VC4&5 
neurodegeneration (n>124 neurons, 62 animals per bar). Single-copy 
overexpression of either the intracellular portion of APP (SC_APPC59) or 
transmembrane and extracellular portion (SC_APPN636) is sufficient to 
induce neurodegeneration and behavioral decline, similar to that seen in the 
SC_APP strain.  Planned Fisher’s exact tests comparing same age WT 
where * P<0.003, ** P<0.00001, n>124 neurons (62 animals) per bar.  
(C,D) Behavioral decline in egg retention (n>48 per bar) (C) and swim 
head-bend frequency (n>20 per bar) (D) in strains that express different 
portions of APP. For panels C and D, statistically compared with planned t-
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Pan-neuronally overexpressed APP accumulates inside select cholinergic neurons 
preceding degeneration in middle age 
The widespread expression of APP in the nervous system of humans belies the 
selective vulnerability of specific cholinergic neurons in AD (Davies et al., 1976; Perry et 
al., 1977).  Similarly, it was unclear why pan-neuronal expression of APP or apl-1 would 
lead to selective degeneration of the VC cholinergic neurons.  To visualize patterns of 
APP expression non-invasively in C. elegans, we constructed new transgenic strains with 
a single copy of C-terminal mCherry-tagged APP or APL-1 (strains SC_APP:mCh and 
SC_apl-1:mCh).  Despite being expressed by a standard pan-neuronal promoter (Prab-3), 
just as in the SC_APP and SC_apl-1 strains above, we only detected mCherry 
fluorescence in the six VC-class cholinergic neurons with confocal microscopy (Figure 
7).  The mCherry signal became apparent in first-day adults, and increased up until 
individual VC neurons died.  In rare individuals that reached advanced age, mCherry 
expression was visible in all VC neurons, but not elsewhere (Figure 8).   
We next generated a series of transgenic strains as controls to test whether 
accumulation could be due to a number of unexpected scenarios.  One possibility is that 
the mCherry protein itself tends to accumulate in VC neurons.  To test this idea, we 
generated a strain that expressed a single copy of mCherry with the same pan-neuronal 
promoter (strain designated SC_mCh); however, we failed to detect any fluorescence as 
might be normally be expected with such a low gene dose (Figure 9A).  In addition, the 







 Figure 7. Pan-neuronally expressed APP accumulates in specific cholinergic 
neurons that degenerate in middle age.   (A,B) Confocal stack images of 
mCherry-tagged APL-1 and APP localization in the midbody and head of 
SC_apl-1 (A) and SC_APP (B) strains. mCherry-tagged protein co-localizes 
in VC4&5 neurons starting on first day of adulthood but is undetectable in 
other areas including head. Brackets highlight area with hundreds of head 
neurons that lack noticeable mCherry signal. Asterisks, gut 
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 Figure 8. Localization of APP in VC-class cholinergic neurons. (A,B) In 
rare animals that reach advanced age (day 10 adults) mCherry-tagged APL-
1 (A) and APP (B) both localize to VC neurons, in addition to surviving 
VC4&5 neurons, in day 10 animals. Green arrows, location of dead neurons; 
asterisks, gut autoflourescence; scale bars, 40 μm. 
 
attributed to an artifact of the Prab-3 promoter because we confirmed that a multiple-
copy extrachromosomal array with a Prab-3::mCherry gene expressed mCherry 
throughout the nervous system from embryonic development onward in WT and our AD 
model backgrounds (Figure 9B,C).  Alternatively, VC neurons might be expected to 
accumulate APP and APL-1 protein if these neurons did not normally express apl-1.  
However, consistent with a previous report (Hornsten et al., 2007), we found that the 
endogenous apl-1 promoter expressed mCherry in the VC neurons and throughout the 
nervous system with a multiple-copy extrachromosomal array in WT and our AD model 
backgrounds (Figure 9D,E).  Lastly, we ruled out that the APP mRNA might lead to 
degeneration because a transgenic strain that overexpressed a version of APP with an 
early stop codon showed no degeneration (Figure 1B).  Thus, we tentatively concluded 
SC_APL-1:MCh Merge 
Day 10 
   
 



















































that the selective accumulation of APP or APL-1 protein in these neurons may be a cause 
of the selective degeneration of VC cholinergic neurons in C. elegans.  
 
 Figure 9. Confirmation that Prab-3 is a pan-neuronal promoter and that 
Papl-1 expresses in VC neurons. (A) A single copy Prab-3::mCherry 
knocked into the genome is found expressed in neurons throughout the 
ventral nerve cord, including VC neurons as indicated by double labeling 
(yellow) with GFP-specific VC neuron reporter (white arrows). (B,C) The 
pan-neuronal promoter Prab-3 expresses mCherry (displayed white) 
throughout nervous system in a SC_APP background (B) and also in VC 
neurons (yellow indicates overlap of red mCherry signal with green VC 
neurons) (C). (D,E) The endogenous promoter region (2kb) of apl-1 
expresses mCherry (displayed white) throughout nervous system in a 
SC_APP background (D) 3 and also in VC neurons (yellow indicates 
overlap of red mCherry signal with green VC neurons) (E). Worms are 
positioned in coiled posture to show entire nervous system and asterisks 
indicate numerous neurons in head in panels D and E. For panels A-D scale 
bars, 40 μm. 
 46 
To test whether the pattern of neurodegeneration and APP accumulation depended 
on factors intrinsic and/or extrinsic to the VC neurons, we generated two additional 
transgenic strains.  One strain used the Ptph-1 promoter to express a single copy of APP 
in VC4&5 neurons and a few other neurons, but not other VC neurons (strain SC_Ptph-
1:APP:mCh).  (Unfortunately, there is no VC-specific promoter)  A second strain used 
the Punc-30 promoter to express a single copy of APP in all GABAergic neurons, 
including some in the nerve cord nearby the VC neurons (strain SC_Punc-30:APP:mCh).  
We found that VC4&5 neurons died in the SC_Punc-30:APP:mCh strain (Fig 10).  This 
strongly suggests the existence of a cell-non autonomous route to patterned 
neurodegeneration.  In addition, we found that VC4&5 neurons also died in the SC_Ptph-
1:APP:mCh strain (Fig 10).  Although this suggests the existence of a cell-autonomous 
route to patterned neurodegeneration, we cannot be conclusive because the Ptph-1 
promoter expresses in a few neurons in addition to VC4&5 neurons.  However, confocal 
imaging revealed that the SC_Ptph-1:APP:mCh strain showed accumulation of APP only 
in the VC4&5 neurons but not in other Ptph-1-expressing neurons, nor other VC neurons 
(Fig 10C).  Imaging of the SC_Punc-30:APP:mCh strain revealed no detectable mCherry 
signal (Fig 10C).  Taken together, our results show that the selective accumulation of 
overexpressed APP is a cell-autonomous, while the patterned degeneration is likely both 









 Figure 10.  Different Expression Patterns of APP can Produce Similar              
Levels of Degeneration and Behavioral Deficits.  (A) Quantification of 
percent VC4&5 neurodegeneration (n>124 neurons, 62 animals per bar). 
Expression of APP under a GABA promoter or 5HT promoter yields similar 
degeneration levels as with the pan-neuronal promoter Prab-3. (B) 
Behavioral decline in egg retention (n>48 per bar) in strains that express 
APP under different promoters. (C) Confocal stack images of mCherry-
tagged APP localization in the midbody of Punc30:APP:mCh and Ptph-
1:APP:mCh.  Expression in 5HT neurons reveal accumulation only in VC 
neurons, while GABA expression revealed no detectable accumulation.  
Scale bars, 40 μm.  (D) Quantification of degenration in animals expressing 
multiple copies of apl-1.  Degeneration is not dependent upon expression 
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To gain insight into the cell-non-autonomous route to degeneration, we generated 
two additional transgenic strains that express a single copy of distinct portions of APP in 
the GABAergic neurons.  Intriguingly, we observed that the VC4&5 neurons died in 
regardless of which portion was expressed in GABAergic neurons (Fig 11).  This 
suggests the possibility of multiple extrinsic routes to patterned neurodegeneration.   
Having established these new worm models of AD with age-related patterned 
cholinergic neurodegeneration, we then combined genetic and pharmacological 
approaches to determine how conserved cell death and immune signaling pathways 






 Figure 11.  VC neurons are vulnerable to degeneration by cell-non-
autonomous expression of disctinct portions of APP.  Both intracellular and 
extracellular portions of APP expressed in GABA neurons is suffcient to 
induce degeration of VC neurons. (WT, SC_mCh, SC_APP, 
SC_Punc30:APP, and SC_tph-1:APP data same as in Figure 10). 
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Apoptotic signaling is required for APP-induced neurodegeneration 
Many highly conserved components of necrotic, apoptotic, and phagocytic 
pathways that underlie cell death have been discovered in C. elegans (Putcha et al., 
2004).  Which ones are essential for APP-induced neurodegeneration?  First, we ruled out 
a role for conventional necrosis because elimination of crt-1, the single homolog of the 
essential necrotic gene calreticulin (Park et al., 2001), had no effect on degeneration 
(Figure 12A).  Next, we found an essential role for apoptosis with several experiments.  
Deletion of egl-1, a homolog of BH3 (Bcl-2 homology region 3) type activators of 
apoptosis in mammals, prevented degeneration (Asterisks denote significant decrease in 
degeneration in egl-1;SC_apl-1 and ced-6; SC_apl-1 strains versus SC_apl-1 in Figure 
12A).  Additionally, deletion of egl-1 partially rescued behavioral defects in SC_APP and 
SC_APL-1 strains (Figure 12B,C).  Conversely, activating apoptotic signaling with a 
gain-of-function mutation in egl-1 did not exacerbate the incidence of degeneration 
(Figure 12A).  Indeed, the egl-1(gf) mutant showed age-related degeneration of VC4&5 
neurons even without APP (or apl-1) overexpression.  Consistent with an essential role 
for apoptosis, deletion of ced-3, a homolog of the mammalian apoptotic caspase-9/ICE, 
similarly prevented degeneration (Figure 12A).  Likewise, elimination of ced-6, the 
homolog of mammalian phagocytotic gene GULP, prevented degeneration and preserved 
function of VC4&5 neurons (Fig. 12A).  This suggests that in our AD models CED-6 has 
a primary apoptotic role to act as a “killer” signal as found in other scenarios (Reddien et 


















 Figure 12. APP induces patterned neurodegeneration via an apoptotic 
pathway that requires egl-1, ced-3, and ced-6.  (A) Quantification of percent 
VC4&5  neurodegeneration in cell-death pathway mutants. Planned Fisher’s 
exact tests where * represents P<0.00001 for comparing same age SC_apl-1 
and n.s., not significant.  # represents P<0.0001 for comparing same age 
WT.  n>124 neurons (62 animals) per bar.  (B,C)  Null mutation in egl-1 
preserved WT-like egg-laying and swimming behaviors in AD model 
strains. For statistical comparisons of egg retention, n>48 animals per bar, 
planned t-tests vs same age WT where **, P<0.05. Error bars, s.e.m.  (D)  
mCherry-tagged APP still accumulates in VC neurons spared from 
degeneration in egl-1(lf) background, inset. Asterisks, gut autoflourescence. 
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degeneration requires members of the conserved apoptotic pathway including EGL-1, 
CED-3, and CED-6.  
If abnormal accumulation of APP (or APL-1) causes degeneration, might 
interference in apoptotic signaling prevent accumulation of APP (or APL-1)?  Instead, we 
found that the level and pattern of mCherry-tagged APP (or APL-1) expression in an egl-
1(null) background was indistinguishable from that of SC_APP:mCh and SC_APL-1:mCh 
strains (Figure 12D).  Our results strongly suggest that apoptotic mutations prevent 
degeneration by blocking APP-triggered entrance into the apoptotic pathway. 
P7C3 prevents APP-induced neurodegeneration while maintaining neural function 
We next tested whether the new putative neuroprotective compound P7C3 could 
also prevent APP-induced degeneration.  P7C3 was recently discovered in an unbiased 
screen for small molecules that increase the number of adult-born neurons in the 
hippocampus of mice, potentially by increasing their survival (preventing their death) 
(Pieper et al., 2010).  The mechanistic basis for the neuroprotective effects of P7C3 
remains unknown (Pieper et al., 2010).  Animals were treated with P7C3 (50 μM) from 
L4-larval stage onward (Figure 2A).  P7C3 treatment significantly prevented 
neurodegeneration induced by APP or apl-1 (Figure 13A).  Degeneration was more 
modestly prevented in the SC_apl-1 strain but not in the SC_APP strain when animals 





 Figure 13. P7C3 and Dimebon prevent APP-induced neurodegeneration by 
blocking entrance to apoptosis.   (A) P7C3 and Dimebon both prevent 
degeneration of VC4&5 neurons.  Planned Fisher’s exact tests comparing 
untreated animals of same age and genotype where *, P<0.00001. (B) Dose-
response curves.  Planned Fisher’s exact tests of treated vs untreated groups 
where *, P<0.00001.  (C) Protective effects of drugs on neurodegeneration 
are not additive in an egl-1(null) background.  Conversely, drugs cannot 
prevent degeneration induced by gain-of-function mutation in egl-1. (D) 
Confocal stack images show that mCherry-tagged APP still accumulates in 
neurons spared from degeneration with treatment of P7C3, inset. Asterisks, 
gut autoflourescence.  Scale bars, 40 mm.  For panels A-C all bars and data 
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be ineffective once the degenerative process has initiated. The structure of P7C3 
resembles Dimebon, a potential drug for AD (Bachurin et al., 2001; Doody et al., 2008; 
Steele et al., 2012).  We found that both drugs prevented neurodegeneration; however, a 
dose-response analysis found that P7C3 was two-orders of magnitude more potent than 
Dimebon (Figure 13B).  To determine whether P7C3 and Dimebon could prevent 
degeneration elicited by distinct portions of APP, we assayed the protective effects of 
each drug on our strains that overexpressed different portions of APP.  Surprisingly, we 
found both drugs prevented degeneration for the SC_APPC59 strain, but failed to provide 
protection for the SC_APPN636 strain (Figure 14).  Protective effects against 
degeneration for the SC_APPC59 strain extended to protection of egg-laying and 
swimming behaviors that depend on the VC4&5 neurons (data not shown).  These results 
suggest that when separated, different portions of human APP molecule may initiate 
apoptotic degeneration via different entrances, only one of which might be blocked by 
P7C3 and Dimebon.  
Next, we used mCherry-tagged transgenes to determine whether the drugs might 
prevent degeneration by stopping accumulation of APP or APL-1.  While drug-treated 
SC_APP:mCh or SC_apl-1:mCh individuals advanced in age without behavioral deficits 
(swimming and egg laying), mCherry-tagged protein accumulated specifically in the VC 
cholinergic neurons (Figure 13D).  To narrow down the point at which these drugs act in 
the neurodegenerative pathway we tested how our AD models responded with different 
apoptotic mutations.  P7C3 and Dimebon offered no further protection from degeneration 
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in an egl-1(null) mutant background (Figure 13C).  Conversely, these drugs failed to 
prevent degeneration in SC_APP and SC_apl-1 strains with a gain-of-function mutation 
in egl-1 (Figure 13C).  Taken together, these results suggest that the drugs act upstream 
of EGL-1 apoptotic signaling.  Thus, P7C3 and Dimebon appear to prevent degeneration 





 Figure 14. P7C3 and Dimebon can prevent degeneration induced by full-
length AP and intracellular APP but not extracellular APP. Quantification of 
VC4&5 neurodegeneration (n>124 neurons, 62 animals per bar). Planned 
Fisher’s exact tests compare vs same age and genotype where *, P<0.001. 
Cell-specific pattern of degeneration and APP accumulation depend inversely on level of 
innate-immune signaling 
Neurodegeneration in AD is accompanied by inflammation and the late onset of 
AD correlates with immunosenescence (Eikelenboom et al., 2012).  AD researchers have 
found evidence for both harmful and protective roles for different aspects of the immune 
system in neurodegeneration (Rivest, 2009).  Although C. elegans does not have an 
adaptive immune system, it shares core components of the innate immune system with 



































































































* * * 
 57 
2012; Youngman et al., 2011).  We sought to explore linkage between innate immune 
signaling and neurodegeneration in our worm models of AD.   We hypothesized that 
compromising immunity through genetic disruption of conserved innate-immune 
molecules might recapitulate the patterned neurodegeneration found in our AD models. 
We first found that a loss-of-function mutation in the key conserved innate-
immune gene, nsy-1, led to the same incidence of degeneration of the VC4&5 neurons, 
albeit precociously relative to our AD models (Fig 15A).  nsy-1 encodes the C. elegans 
ortholog of Apoptotic Signaling Kinase 1 (ASK1/MAP kinase kinase kinase) (Wes and 
Bargmann, 2001; Sagasti et al., 2001).  Combining nsy-1(lf) with SC_APP did not hasten 
the onset nor increase the incidence of degeneration (Fig 15A) suggesting that the two act 
in the same genetic pathway for degeneration.  Consistent with this idea, degeneration 
appeared to be primarily apoptotic because an egl-1(lf) mutation prevented degeneration 
in nsy-1(lf);SC_APP worms (Fig 7A).  We also found that loss-of-function mutations in 
any of three additional conserved components of the ASK1/p38 MAPK innate-immune 
signaling axis led to identical levels of degeneration of VC4&5 neurons (tir-1, Toll-
interleukin receptor domain containing receptor ortholog of human SARM; sek-1, MAP 
kinase kinase; and mpk-1, p38 MAP Kinase 1; Fig 15A).  Cholinergic neurons other than 





















































































































 Figure 15. Vulnerability of patterned cholinergic neurodegeneration and 
APP accumulation depends inversely on level of innate immune signaling.  
(A) Quantification of VC4&5 neurodegeneration in innate-immune pathway 
mutants. Immunocompromised mutants display same pattern of VC4&5 
degeneration as AD model worms. P7C3 prevents degeneration in nsy-1(lf) 
mutant backgrounds.  Planned Fisher’s exact tests comparing untreated 
animals of same age and genotype where *, P<0.00001 and n.s., not 
significant, n>124 neurons (62 animals) per bar.  (B)  Confocal stack images 
show that less mCherry-tagged APP accumulates in neurons spared from 
degeneration in nsy-1(gf) mutant background. Location of degenerated VC5 
neuron indicated by blue arrow. (C) Quantification of intracellular 
accumulated mCherry-tagged APP by ratio of average red:green  signals in 




and VB neurons out of 100 animals investigated).  These results suggest a role for innate-
immunity in preserving VC neurons in the presence and absence of overexpressed APP. 
The ASK1/p38MAPK pathway was previously found to regulate calcium 
signaling in C. elegans neurons downstream of the highly conserved kinase CaMKII 
(Sagasti et al., 2001; Chuang et al., 2005; Bezprozvanny et al., 2008; Berridge et al., 
2010).  To determine whether CaMKII influenced degeneration, we assessed 
degeneration of VC4&5 neurons in the CaMKII knock-out mutant unc-43(e408).  We 
found that deletion of unc-43 had no effect on progression of degeneration (Sup Figure 
9A).  We thus conclude that the ASK1/p38MAPK pathway plays a role independent of 
its calcium signaling role in neurons to influence neurodegeneration. 
If the ASK1/p38MAPK immune pathway is protective, then boosting innate 
immune signaling through gain-of-function mutation in the nsy-1 gene might prevent 
degeneration in our AD model.  We found that nsy-1(gf) conferred neuroprotective 
effects and maintained neuronal function of the VC neurons (Fig 15A).  Protection by the 
nsy-1(gf) mutation may be achieved in part by reducing levels of APP protein because 
confocal imaging revealed that intracellular levels of mCherry-tagged APP in VC4&5 
neurons were reduced by 60% (Fig 15B,C).  Protection was also conferred by expressing 
a wild-type copy of nsy-1 with the cholinergic promoter (Punc-17) in nsy-1(lf) and 
SC_APP backgrounds (Fig 15A).  Intriguingly, we found that P7C3 prevented VC 
neurons from dying in nsy-1(lf) and pmk-1(lf) mutants (Fig 15A).  This further refines 
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genetically where P7C3 must function to protect neurons: downstream of 
p38MAPK/PMK-1 and upstream of EGL-1.   
Taken together, our results demonstrate that the conserved ASK1/p38MAPK 
innate immune axis is required to protect the VC-class cholinergic neurons cell-
autonomously from accumulating APP and degenerating in adulthood (Fig 16).  This 
strongly suggests that accumulated APP may selectively kill VC neurons in coordination 












 Figure 16. Working model of APP-induced patterned neurodegeneration.  
APL-1 or APP accumulates in VC neurons to a level that activates a 
conserved apoptotic pathway.  The TIR-1/NSY-1/SEK-1/PMK-1 innate 
immune cascade inhibits accumulation of APL-1/APP until 
immunosenescence commences in middle age.  The drugs P7C3 and 
Dimebon block entrance to apoptosis triggered by accumulated APP or 
APL-1 compromised immune signaling.  This model cannot discern the 
contributions of cell-autonomous versus non-autonomous routes leading to 
accumulation; both have been shown to influence degeneration.  
Mammalian orthologs listed after C. elegans equivalent. Connections reflect 













































Many human neurodegenerative diseases, including AD, paradoxically present an 
initially limited pattern of degeneration caused by alteration of genes that are near-
ubiquitously expressed throughout the brain (Gotz et al., 2009).  Here we use C. elegans 
to provide a clear example of how widespread overexpression of a wild-type protein 
(APP or APL-1) can cause a specific pattern of neurodegeneration (VC-class cholinergic 
neurons) through selective accumulation in middle age.  Accumulated APP triggers the 
death of cells by apoptosis coincident with decline of the neuroprotective ASK1/p38 
MAPK innate immune pathway.  To our knowledge, this study provides the first example 
of neurodegeneration in an AD-related C. elegans model, as well as, the first example of 
apoptosis of adult cells in C. elegans (excluding germ cells).  In addition, although many 
in vitro and in situ studies have implicated apoptosis as the primary mediator of 
degeneration in mouse models of AD (e.g. Cotman et al., 2005), we believe this is the 
first in vivo evidence that deletion of apoptotic genes prevents APP-induced 
neurodegeneration.   
The pattern of APP-induced neurodegeneration seems to be restricted to the VC-
class cholinergic neurons because unique behavioral defects of the AD model strains 
could be accounted for by the death of these neurons alone.  This pattern of 
neurodegeneration perfectly matches the exclusive pattern of mCherry-tagged APP and 
APL-1 protein accumulation in the VC neurons.  Other neurons presumably expressed 
these proteins at levels undetectable by confocal imaging.  This would be consistent with 
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how mCherry was undetectable in our additional control strain that expressed a single 
copy of the mCherry gene driven by a pan-neuronal promoter (Figure S5A).  Thus, we 
conclude that the intracellular pattern of accumulated APP or APL-1 protein causes the 
pattern of neurodegeneration.  Our finding that both worm APL-1 or human APP induced 
an identical pattern of neurodegeneration provides strong evidence that the molecular 
basis of this phenomenon is ancient and conserved. 
Researchers have debated which portions of the APP molecule contribute the 
most to degeneration in AD (Benilova et al., 2012).  In the most popular paradigm, 
abnormal proteolytic cleavage of the extracellular/transmembrane portion of APP 
contributes to neurodegeneration.  The most toxic components are currently believed to 
be soluble variants of the Aβ  peptide (Huang et al., 2012).  In an alternate paradigm, 
overexpression of the intracellular portion of APP alone recapitulated common aspects of 
degeneration found in Aβ-mouse models (Ghosal et al., 2009).  Our results with 
C. elegans support both paradigms, showing for the first time in a single study that 
distinct portions of human APP can induce the same cellular pattern of 
neurodegeneration.  This surprising result suggests that future AD studies might do well 
to focus on why certain cholinergic neurons die irrespective of the APP-derived toxic 
peptide.   
Consistent with the toxicity of different portions of APP, previous studies in 
C. elegans have found that overexpression of multiple copies of Aβ produces toxicity 
when expressed in muscle, and that overexpression of multiple copies of WT full-length 
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APP or apl-1 causes partial lethality and behavioral dysfunction when expressed 
throughout the nervous system (Hornsten et al., 2007; Link et al., 2003; Ewald et al., 
2012).  The convenience of C. elegans transgenesis will enable further study of how 
different portions of APP induce patterned neurodegeneration at doses relevant to human 
disease. 
It remains puzzling why only the VC neurons accumulate APP and APL-1 
proteins.  We consider several possibilities.  First, these genes may be expressed at toxic 
levels due to certain cis-regulatory elements specific for the VC neurons.  This seems 
unlikely, however, because we found the same results with the endogenous apl-1 
promoter and a conventional pan-neuronal promoter.  In our control experiments, both 
promoters drove expression of mCherry in VC neurons as well as many other neurons 
from embryonic stage onward.   Second, the APP and apl-1 mRNA might be degraded 
efficiently in all cells except for the VC neurons.  Degradation cannot be so efficient, 
however, because we found that both genes were expressed at levels two-fold higher as 
expected.  Third, the APP and APL-1 proteins might be degraded efficiently in all cells 
expect for the VC neurons.  This hypothesis is consistent with how mCherry-tagged 
versions of these proteins became visible in early adulthood and intensified into middle 
age until neurons died.  Perhaps the VC neurons lack a proteolytic component critical for 
amyloidogenic proteins (Silva et al., 2011).  Our finding that mCherry-tagged APP 
accumulated less after boosting innate immunity through nsy-1(gf) mutation fits with this 
theory.   The innate immune system in mammals has been found to work with other cell 
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defense systems to promote proteasomal degradation of abnormal proteins and prevent 
apoptosis (Krüger and Kloetzel, 2012). 
Another way to think about why VC neurons die and other neurons survive is to 
ask what is unique about VC neurons.  The VC neurons represent only six of the ~124 
cholinergic neurons in the C. elegans nervous system (J. Rand, personal communication; 
Duerr et al., 2008).  They are distinct from other cholinergic neurons in that they arise 
post-embryonically, undergo synaptogenesis during the adult stage, and acquire their 
cholinergic fate independent of the conserved COE-type transcription factor UNC-3 
(Sulston et al., 1983; Kratsios et al., 2011; Potts et al., 2009).  In older WT animals, we 
also found that VC neurons show a higher basal level of degeneration relative to other 
cholinergic neurons (Figure 1D).  This may be an apoptotic process because basal 
degeneration was slightly reduced in an ICE/ced-3 mutant background (Figure 5A).  The 
developmental lineage for VC neurons is also distinct from other cholinergic neurons.  
During development, cells that are orthologous to the VC neurons in the nerve cord 
naturally undergo apoptosis (Sulston et al., 1983).  We speculate that the VC neurons 
may contain a factor(s) that delays their developmental apoptosis until old age, and that 
accumulation of APP or disruption of innate immune signaling may hasten this process.  
A similar process might eventually be found to explain patterned degeneration of 
cholinergic neurons in mammals. 
Many of the traits of VC neurons described above are intriguingly reminiscent of 
the adult-born cholinergic neurons in the hippocampus in mammals.  During adult 
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neurogenesis, a stem cell is thought to divide into four precursor cells (Li et al., 2009).  
Three of these usually undergo apoptosis, but the surviving cell differentiates into a 
neuron that participates in the processing of newly formed memories (Sierra et al., 2010; 
Li et al., 2009; Rodriquez et al., 2009).  Like the VC neurons, these adult-born 
cholinergic neurons are selectively vulnerable to degeneration in AD models and natural 
aging (Rodriquez et al., 2009).   
Although C. elegans lacks adaptive immunity, it shares an ancestral core cassette 
of innate immune molecules with mammals including orthologs of ASK1 and p38 
MAPKinase1 (Pukkila-Worley and Ausubel, 2012; Matsuzawa et al., 2005).   Our 
findings that weakening innate immunity hastened degeneration, while strengthening 
innate immunity prevented APP accumulation and neurodegeneration suggest that this 
conserved branch of innate immunity might play a similar role in preventing APP-
induced degeneration in mammals.  Boosting innate immunity through gain-of-function 
mutation in the worm ASK1 ortholog NSY-1 was previously shown to prevent 
degeneration of dopamine neurons after exposure to the toxins 6-hydroxydopamine and 
methamphetamine (Schreiber and McIntire, 2011).  Although, hyperactivation of the 
ASK1/p38MAP kinase pathway is  suspected of causing cell death in mammals (KO of 
ASK1 relieves indiscriminate killing of cells by astrocytes in a mouse model of MS (Guo 
et al., 2010)) and in worms (KO of the p38MAP kinase ortholog in C. elegans prevented 
excessive apoptotic death of germ cells by Salmonella (Aballay et al., 2003)), strategies 
to prevent neurodegeneration in AD by only modestly boosting specific branches of 
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innate immune signaling are currently being tested in rodent models (Rezai-Zadeh et al., 
2011; Butchart and Holmes, 2012).  
While it may be expected that the level of the innate immune signaling might 
dictate the temporal pattern of neurodegeneration, we unexpectedly found that it also 
dictated the spatial pattern of neurodegeneration.  In either the presence or absence of 
overexpressed APP or apl-1, we found that the same VC neurons degenerated in tir-1, 
nsy-1, sek-1 and pmk-1 loss-of-function mutants at the same incidence via apoptosis. The 
identical pattern of limited neurodegeneration is intriguing because apl-1 and innate 
immune genes are all widely expressed in C. elegans.  We propose that the cellular 
pattern of APP-induced neurodegeneration may be explained by the VC neurons being 
more heavily dependent on innate immune signaling for the clearance of toxic proteins 
relative to other neurons.  We suspect that the low level of degeneration of the VC 
neurons in WT as well as the degeneration in immunocompromised strains may reflect 
accumulation of endogenous APL-1 protein.  Likewise, the timing of immunosenescence 
in C. elegans, which starts on third day of adulthood, may explain the onset of VC 
degeneration in WT.  It will be interesting to determine whether the subset of cholinergic 
neurons that dies first in rodent models of AD also matches those vulnerable in 
immunocompromised mice.  In line with this theory, recent reports found that repeated 
systemic challenge to the immune system caused a spatial pattern of neurodegeneration 
and behavioral symptoms that mimicked AD in mice (Meyer et al., 2008; Krstic et al., 
2012).   
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We also demonstrated the ease in which drugs can be tested for in vivo 
neuroprotective effects with C. elegans.  In less than one week, protective effects can be 
accessed by direct visualization of fluorescently labeled cholinergic neurons.  Moreover, 
the functional integrity of these specific neurons can be assessed with simple behavioral 
assays.  In contrast to most AD drugs in clinical trials that aim to reduce accumulation of 
APP and plaques, we show that P7C3 represents a novel drug class because it can prevent 
apoptotic degeneration and preserve neuronal function even in the face of APP 
accumulation.  Because P7C3 and Dimebon show favorable pharmacological profiles in 
mice and humans respectively (Pieper et al.,2010; Doody et al., 2008), our results 
validate the use of C. elegans for the evaluation of potentially beneficial compounds in 
the treatment of AD and other neurodegenerative disorders with unprecedented speed and 
cost effectiveness. 
P7C3 was found in a screen for small molecules that increase yield of adult-born 
hippocampal neurons in rodent models of aging and mental retardation (Pieper et al. 
2010).  They proposed that P7C3 may promote neurogenesis by preventing the apoptotic 
death of the precursor cells mentioned above.  If so, the anti-apoptotic effects did not 
interfere with natural apoptosis during development because development of mice was 
normal with pre- or post-embryonic treatment with P7C3 (Pieper et al., 2010). Likewise, 
we found that P7C3 did not interfere with developmental apoptosis in C. elegans (data 
not shown).  Considering both rodent and worm studies, these drugs appear to selectively 
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block a “pathological” or “adult” entrance to apoptosis – one conserved across diverse 
neurological disease and species separated by 1 billion years of evolution.   
We also found neuroprotective effects for the structurally similar compound 
Dimebon.  P7C3 and Dimebon both appear to block a pathological entrance to apoptosis 
triggered by accumulation of APP.  Through genetic analysis, we narrowed the point of 
action of these two drugs to a position upstream of the conserved BH3-domain containing 
cell death activator EGL-1, and downstream of the conserved ASK1 innate immune 
signaling triple kinase NSY-1.  Likewise, Dimebon has been shown to protect against 
degeneration and neuronal dysfunction in rodent models of AD, perhaps due to its ability 
to boost beneficial autophagy as demonstrated in cultured neurons (Steele et al., 2012).  
In humans, Dimebon originally showed promise in reducing AD symptoms, but had no 
beneficial effect in recent phase III clinical trials (Doody et al., 2008).   With this new 
mechanistic understanding, future drug trials for AD may consider compounds based on 
the more potent P7C3 to fill the void left by Dimebon.  Because P7C3 also generalized to 
prevent apoptotic neurodegeneration caused by interrupting innate immune signaling, we 
predict that P7C3 may further generalize to protect neurons in diverse degenerative 
disorders. 
Age-related patterned neurodegeneration caused by a widely expressed protein is 
a paradoxical phenomenon observed in all major neurodegenerative disorders (Gotz et 
al., 2009).  These findings of patterned neurodegeneration caused by APP in the well-
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defined nervous system of C. elegans may yield general insight into mechanisms and 







2012 Alzheimer’s Disease Facts and Figures. 
 
Alberts B (2008) The promise of cancer research. Science 320: 19. 
 
Alzheimer’s Disease International Consortium, 2009. 
 
Bertram L, Tanzi RE (2008) Thirty years of Alzheimer’s disease genetics:  the 
implications of systematic meta-analyses.  Nat Rev Neurosci. 10: 768-78. 
 
Block ML, Hong JS (2007) Chronic microglial activation and progressive 
dopaminergic neurotoxicity. Biochem Soc Trans. 35: 1127-32. 
 
Boillee S, Vande Velde C, and Cleveland DW (20016) ALS: a disease of motor 
neurons and their nonneuronal neighbors. Neuron 52:39-59. 
 
Burns A and Lliffe S (2009) Alzheimer’s disease. BMJ 338: 467-471. 
 
Calhoun ME, Burgermeister P, Phinney AL, Stalder M, Tolnay M, Wiederhold KH, 
Abramowski D, Sturchler-Pierrat C, Sommer B, Staufenbeil M, Juker M (1999) 
Neuronal overexpression of mutant amyloid precursor protein results in prominent 
deposition of cerebrovascular amyloid. Proc Natl Acad Sci USA. 96: 14088-93. 
 
Chin J (2011) Selecting a mouse model of Alzheimer’s disease. Methods Mol Biol. 
670: 169-89. 
 
D'Amelio M, Cavallucci V, Middei S, Marchetti C, Pacioni S, Ferri A, Diamantini 
A, De Zio D, Carrara P, Battistini L, Moreno S, Bacci A, Ammassari-Teule M, Marie 
H, Cecconi F (2011) Caspase-3 triggers early synaptic dysfunction in a mouse model 
of Alzheimer’s disease. Nat Neurosci. 14: 69-76. 
 
Davie CA (2008) A review of Parkinson’s disease. Br. Med. Bull. 86: 109-27. 
 
Eikelenboom P, Bate C, Van Gool WA, Hoozemans JJ, Rozemuller JM, Veerhuis R, 
Williams A (2002) Neuroinflammation in Alzheimer’s disease and prion disease. 
Glia 40: 232-9. 
 
 71 
Estrada Sanchez AM, Mejia-Toiber J, and Massieu L (2008) Exitotoxic neuronal 
death and the pathogenesis of Huntington’s disease. Arch. Med. Res. 39: 265-76. 
 
Frokjaer-Jensen C, Davis MW, Hopkins CE, Newman BJ, Thummel JM, Olesen SP, 
Grunnet M, Jorgensen EM (2008) Single-copy insertion of transgenes in 
Caenorhabditis elegans. Nat Genet. 40: 1375-83. 
 
Fuchs, Y and Steller, H (2011) Programmed cell death in animal development and 
disesase. Cell 147:742-58. 
 
Ghosal K, Vogt DL, Liang M, Shen Y, Lamb BT, Pimplikar SW (2009) Alzheimer’s 
disease-like pathological features in transgenic mice expressing the APP intracellular 
domain.  Proc Natl Acad Sci USA.  106: 18367-72.   
 
Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, Giuffra L, 
Haynes A, Irving N, James L (1991) Segregation of a missense mutation in the 
amyloid precursor protein gene with familial Alzheimer’s disease. Nature 21: 704-6. 
 
Goedert M, Sisodia SS, Price DL (1991) Neurofibrillary tangles and beta-amyloid 
deposits in Alzheimer’s disease. Curr Opin Neurobiol. 1:441-7. 
 
Guerreiro, R Wojtas A, Bras J, et al. (2012) TREM2 Variants in Alzheimer’s Disease 
N Engl J Med DOI: 10.1056/NEJM oa1211851. 
 
Hardy J (2006) A hundred years of Alzheimer’s disease research.  Neuron 52: 3-13. 
 
Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo 
MM, Abraham R, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Jones 
N, Stretton A,Thomas C, Richards A, Ivanov D, Widdowson C, Chapman 
J, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill 
M, Lawlor B, Lynch A,Brown KS, Passmore PA, Craig D, McGuinness B, Todd 
S, Holmes C, Mann D, Smith AD, Beaumont H, Warden D, Wilcock G, Love 
S, Kehoe PG, Hooper NM,Vardy ER, Hardy J, Mead S, Fox NC, Rossor M, Collinge 
J, Maier W, Jessen F, Rüther E, Schürmann B, Heun R, Kölsch H, van den Bussche 
H, Heuser I,Kornhuber J, Wiltfang J, Dichgans M, Frölich L, Hampel H, Gallacher 
J, Hüll M, Rujescu D, Giegling I, Goate AM, Kauwe JS, Cruchaga C, Nowotny 
P, Morris JC,Mayo K, Sleegers K, Bettens K, Engelborghs S, De Deyn PP, Van 
Broeckhoven C, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam 
R, Deloukas P, Al-Chalabi A, Shaw CE, Tsolaki M, Singleton AB, Guerreiro 
R, Mühleisen TW, Nöthen MM, Moebus S, Jöckel KH, Klopp N, Wichmann 
HE, Pankratz VS, Sando SB,Aasly JO, Barcikowska M, Wszolek ZK, Dickson 
DW, Graff-Radford NR, Petersen RC; Alzheimer's Disease Neuroimaging 
Initiative, van Duijn CM, Breteler MM,Ikram MA, DeStefano AL, Fitzpatrick 
 72 
AL, Lopez O, Launer LJ, Seshadri S; CHARGE consortium, Berr C, Campion 
D, Epelbaum J, Dartigues JF, Tzourio C,Alpérovitch A, Lathrop M; EADI1 
consortium, Feulner TM, Friedrich P, Riehle C, Krawczak M, Schreiber S, Mayhaus 
M, Nicolhaus S, Wagenpfeil S, Steinberg S,Stefansson H, Stefansson K, Snaedal 
J, Björnsson S, Jonsson PV, Chouraki V, Genier-Boley B, Hiltunen M, Soininen 
H, Combarros O, Zelenika D, Delepine M, Bullido MJ, Pasquier F, Mateo I, Frank-
Garcia A, Porcellini E, Hanon O, Coto E, Alvarez V, Bosco P, Siciliano G, Mancuso 
M, Panza F, Solfrizzi V, Nacmias B,Sorbi S, Bossù P, Piccardi P, Arosio B, Annoni 
G, Seripa D, Pilotto A, Scarpini E, Galimberti D, Brice A, Hannequin D, Licastro 
F, Jones L, Holmans PA,Jonsson T, Riemenschneider M, Morgan K, Younkin 
SG, Owen MJ, O'Donovan M, Amouyel P, Williams J (2011) Common variants at 
ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with 
Alzheimer’s disease. Nat Genet. 43:429-435. 
 
Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones 
RW, Bullock R, Love S, Neal JW, Zotova E, Nicoll JA (2008) Long-term effects of 
abeta42 immunisation in Alzheimer’s disease:  Follow-up of a randomized, placebo-
controlled phase 1 trial. Lancet 372: 216-23. 
 
Hornsten A, Lieberthal J, Faida S, Malins R, Ha L, Xu X, Daigle I, Markowitz M, 
O’Connor G, Plasterk R, Li C (2007) APL-1, a Caenorhabditis elegans protein related 
to the human beta-ayloid precursor protein, is essential for viability. Proc Natl Acad 
Sci USA. 104: 1971-6. 
 
Howlet DR, Richardson JC (2009) The pathology of APP transgenic mice:  a model 
of Alzheimer’s disease or simply overexpression of APP?.  Histol Histopahtol.  24: 
83-100. 
 
Iqbal K, Alonso Adel C, Chen S, Chohan MO, El-Akkad E, Gong CX, Khatoon S, Li 
B, Liu F Rahman A, Tanimukai H, Grundke-Iqbal I (2005) Taue pathology in 
Alzheimer disease and other tauopoathies. Biochem Biophys Acta. 1739: 198-210. 
 
Iwatsubo T, Hasegawa M, Ihara Y (1994) Neuronal and glial tau-positive inclusions 
in diverse neurologic diseases share common phosphorylation characteristics. Acta 
Neuropathol. 88: 129-36. 
 
Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, Stefansson H, 
Sulem P, Gudbjartsson D, Maloney J, Hoyte K, Gustafson A, Liu Y, Lu Y, Bhangale 
T, Graham RR, Huttenlocher J, Bjornsdottier G, Andreassen OA, Jonsson EG, Palotie 
A, Behrens TW, Magnusson OT, Kong A, Thorsteinsdottir U, Watts RJ, Stefansson K 
(2012) A mutation in APP protects against Alzheimer’s disease and age-related 
cognitive decine. Nature 488:96-9. 
 
 73 
Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, Bjornsson 
S, Huttenlocher J, Levey AI, Lah JJ, Rujescu D, Hampel H, Giegling I, Andreassen 
OA, Engedal K, Ulstein I, Djurovic S, Ibrahim-Verbaas C, Hofman A, Ikram MA, 
van Duijn CM, Thorsteinsdottir U, Kong A, Stefansson K (2013) Variant of TREM2 
associated with the risk of Alzheimer’s disease. N Engl J Med. 10: 107-16. 
 
Kitazawa M, Medeiros R, and Laferla FM (2012) Transgenic mouse models of 
Alzheimer disease: Developing a better model as a tool for therapeutic interventions 
Curr. Pharm Des. 18: 1131-47. 
 
LaFerla FM (2002) Calcium Dyshomeostasis and intracellular signaling in 
Alzheimer’s disease Nat. Rev. Neurosci. 3: 862-72. 
 
Lalonde R, Fukuchi K, and Strazielle C (2012) Neurologic and motor dysfunctions in 
APP transgenic mice Rev Neurosci 23: 363-79. 
Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, Combarros 
O, Zelenika D, Bullido MJ, Tavernier B, Letenneur L, Bettens K, Berr C, Pasquier 
F, Fiévet N, Barberger-Gateau P, Engelborghs S, De Deyn P, Mateo I, Franck 
A, Helisalmi S, Porcellini E, Hanon O; European Alzheimer's Disease Initiative 
Investigators, de Pancorbo MM, Lendon C, Dufouil C, Jaillard C, Leveillard 
T, Alvarez V, Bosco P, Mancuso M, Panza F, Nacmias B, Bossù P, Piccardi 
P, Annoni G, Seripa D, Galimberti D, Hannequin D, Licastro F, Soininen H, Ritchie 
K, Blanché H, Dartigues JF, Tzourio C, Gut I, Van Broeckhoven C, Alpérovitch 
A, Lathrop M, Amouyel P (2009) Genome-wide association study identifies variants 
at CLU and CR1 associated with Alzheimer’s disease. Nat Genet. 41: 1094-9. 
 
Leroy K, Ando K, Laporte V, Dedecker R, Suain V, Authelet M, Heraud C, Pierrot 
N, Yilmaz, Z, Octave J, Brion, J (2012) Lack of Tau proteins rescues neuronal cell 
death and decreases amyloidogenic processing of APP in APP/PS1 mice.  American 
Journal of Pathology 181: 1928-40. 
 
Louneva N, Cohen JW, Han LY, Talbot K, Wilson RS, Bennett DA, Trojanowski JQ, 
Arnold SE (2008) Caspase-3 is enriched in postsynaptic densities and increased in 
Alzheimer’s disease. Am J Pathol. 173: 1488-95. 
 
Mattson MP (1997) Cellular actions of beta-amyloid precursor protein and its soluble 
and fibrillogenic derivatives. Physiol Rev. 77: 1081-132. 
 
Meziane H, Dodart JC, Mathis C, Little S, Clemens J, Paul SM, Ungerer A (1998) 
Memory-enhancing effects of secreted forms of the beta-amyloid precursor protein in 
normal and amnestic mice. Proc Natl Acad Sci USA. 95: 12683-8. 
 
 74 
Minghetti L (2005) Role of inflammation in neurodegenerative diseases. Curr Opin 
Neurol. 18: 315-21. 
 
Mudher A and Lovestone S (2002) Alzheimer’s disease-do tauists and Baptists finally 
shake hands? Trends Neurosci. 25: 22-6. 
 
Napoli I, Neumann H (2009) Microglial clearance function in health and disease. 
Neuroscience 158: 1030-8. 
 
Ness S, Rafii M, Aisen P, Krams M, Silverman W, Manji H (2012) Down’s 
syndrome and Alzheimer’s disease: Towards secondary prevention. Nat Rev Drug 
Discov. 9: 655-6. 
 
Pohanka M (2011) Cholinesterases, a target of pharmacology and toxicology. Biomed 
Pap Med Fac Univ Palacky Olomouc Czech Repub. 155: 219-29. 
 
Priller C, Bauer T, Mitteregger G, Krebs B, Kretzschmar HA, Herms J (2006) 
Synapse formation and function is modulated by the amyloid precursor protein. J 
Neurosci. 27:7212-21. 
 
Proskuryakov SY, Konoplyannikov AG, Gabai VL (2003) Necrosis:  A specific form 
of programmed cell death? Exp Cell Res. 283: 1-16. 
 
Putcha GV, Johnson EM Jr (2004) Men are but worms:  neuronal cell death in C. 
elegans and vertebrates.  Cell Death Differ. 11: 38-48. 
 
Ribe EM, Serrano-Saiz E, Akpan N, Troy CM (2008) Mechanisms of neuronal death 
in disease: defining the models and the players. Biochem J 415: 165-182. 
 
Seshadri S, Fitzpatrick AL, Ikram MA, DeStefano AL, Gudnason V, Boada M, Bis 
JC, Smith AV, Carassquillo MM, Lambert JC, Harold D, Schrijvers EM, Ramirez-
Lorca R, Debette S, Longstreth WT Jr, Janssens AC, Pankratz VS, Dartigues 
JF, Hollingworth P, Aspelund T, Hernandez I, Beiser A, Kuller LH, Koudstaal 
PJ,Dickson DW, Tzourio C, Abraham R, Antunez C, Du Y, Rotter JI, Aulchenko 
YS, Harris TB, Petersen RC, Berr C, Owen MJ, Lopez-Arrieta J, Varadarajan 
BN,Becker JT, Rivadeneira F, Nalls MA, Graff-Radford NR, Campion D, Auerbach 
S, Rice K, Hofman A, Jonsson PV, Schmidt H, Lathrop M, Mosley TH, Au R, Psaty 
BM, Uitterlinden AG, Farrer LA, Lumley T, Ruiz A, Williams J, Amouyel 
P, Younkin SG, Wolf PA, Launer LJ, Lopez OL, van Duijn CM, Breteler 
MM; CHARGE Consortium; GERAD1 Consortium; EADI1 Consortium (2010) 




Shanley DP, Aw D, Manley NR, Palmer DB (2009) An evolutionary perspective on 
the mechanisms of immunosenescence. Trends Immunol. 30: 374-81. 
 
Small SA, Duff K (2008) Linking Abeta and tau in late-onset Alzheimer disease:  a 
dual pathway hypothesis. Neuron. 60: 534-42. 
 
Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, 
Ledermann B, Burki K, Frey P, Paganetti PA, Waridel C, Calhoun ME, Jucker M, 
Probst A, Staufenbiel M, Sommer B  (1997)Two amyloid precursor protein 
transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci 
USA.  94: 13287-92. 
 
Su JH, Zhao M, Anderson AJ, Srinivasan A, Cotman CW (2001) Activated caspase-3 
expression in Alzheimer’s and aged control brain: correlation with Alzheimer 
pathology. Brain Res. 898: 350-7. 
 
Takahashi K, Prinz M, Stagi M, Chechneva O, Neumann H (2007) TREM2-
transduced myeloid precursors mediate nervous tissue debris clearance and facilitate 
recovery in an animal model of multiple sclerosis. PLoS Med. 4:e124. 
 
Ting JT, Kelley BG, Lambert TJ, Cook DG, Sullivan JM (2007) Amyloid precursor 
protein overexpression depresses excitatory transmission through both presynaptic 
and postsynaptic mechanisms. Proc Natl Acad Sci USA. 104: 353-8. 
 
Town T, Tan J, Flavell RA, Mullan M (2005) T-cells in Alzheimer’s disease. 
Neuromolecular Med. 7: 255-64. 
 
Turner PR, O’Connor K, Tate WP, Abraham WC (2003) Roles of amyloid precursor 
protein and its fragments in regulating neural activity, plasticity and memory. Prog 
Neurobiol. 70: 1-32. 
Yamada K, Yabuki C, Seubert P, Schenk D, Hori Y, Ohtsuki S, Terasaki T, 
Hashimoto T, Iwatsubo T (2009) Abeta immunotherapy:  Intracerebral sequestration 
of abeta by an anti-abeta monoclonal antibody 226 with high affinity to soluble abeta. 
J Neurosci. 29: 11393-8. 
 
Zheng H and Koo EH (2006) The amyloid precursor protein: Beyond amyloid. Mol 







Aballay A, Drenkard E, Hilbun LR, Ausubel FM. (2003) Caenorhabditis elegans innate 
immune response triggered by Salmonella enterica requires intact LPS and is mediated 
by a MAPK signaling pathway. Curr Biol. 13: 47-52. 
 
Ashe, KH and Zahs, KR (2010) Probing the biology of Alzheimer’s disease in mice. 
Neuron 66: 631-45. 
 
Bachurin, S, Tkachenko, S, Baskin, I, Lermontova, N, Mukhina, T, Petrov, L, 
Ustinov, A, Proshin, A, Grigoriev, V, Lukoyanov, N, Payulin, V, and Zefirov, N (2001) 
Anithistamine agent Dimebon as a novel neuroprotector and cognition enhancer. Ann N Y 
Acad Sci 939: 425-35. 
 
Benilova, I, Karran, E, and De Strooper, B (2012) The toxic Aβ oligomer and 
Alzheimer’s disease: an emperor in need of clothes. Nat Neurosci 15: 349-57. 
 
Bertram, L and Tanzi, RE (2008) Thirty years of Alzheimer’s disease genetics: the 
implications of systematic meta-analyses. Nat Rev Neurosci. 10: 768-78 . 
 
Bowen, DM, Smith, CB, White, P, Davison, AN (1976) Neurotransmitter-related 
enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain 99: 
459-96. 
 
Brenner, S (1974) The genetics of Caenorhabditis elegans. Genetics 77: 71–94. 
 
Butchart, J and Holmes, C (2012) Systemic and central immunity in Alzheimer's disease: 
therapeutic implications. CNS Neurosci Ther. 18: 64-76. 
 
Cotman, CW, Poon, WW, Rissman, RA, and Blurton-Jones, M (2005) The role of 
caspase cleavage of tau in Alzheimer disease neuropathology. J Neuropathol Exp 
Neurol. 64: 104-12. 
 
Daigle, I and Li, C (1993) apl-1, a Caenorhabditis elegans gene encoding a protein 
related to the human beta-amyloid protein precursor. Proc Natl Acad Sci U S A. 90: 
12045-9. 
 
Davies, P and Maloney, AJ (1976) Selective loss of central cholinergic neurons in 
Alzheimer’s disease. Lancet 2: 1403. 
 
De Calignon, A, Polydoro, M, Suarez-Calvet, M, William, C, Adamowicz, DH, 
Kopeikina, KJ, Pitstick, R, Sahara, N, Ashe, KH, Carlson, GA, Spires-Jones, TL, 
Hyman BT (2012) Propagation of tau pathology in a model of early Alzheimer’s 
disease. Neuron 73: 685-97. 
 
 77 
Doody, RS, Gavrilova, SI, Sano, M, Thomas, RG, Aisen, PS, Bachurin, SO, 
Seely L, Hung D (2008) Effect of dimebon on cognition, activities of daily living, 
behavior, and global function in patients with mild-to-moderate Alzheimer’s disease: a 
randomized, double-blind, placebo-controlled study. Lancet 372: 207-15. 
 
Duerr, JS, Han, HP, Fields SD, and Rand JB (2008) Identification of major classes 
of cholinergic neurons in the nematode Caenorhabditis elegans. J Comp Neurol. 506: 
398-408. 
 
Eikelenboom, P, van Exel, E, Veerhuis, R, Rozemuller, AJ, van Gool, WA, 
Hoozemans, JJ (2012) Innate immunity and the etiology of late-onset Alzheimer's 
disease. Neurodegener Dis. 10: 271-3. 
 
Ewald, CY, Cheng, R, Tolen, L, Shah, V, Gillani, A, Nasrin, A, and Li, C (2012) 
Pan-Neuronal Expression of APL-1, an APP-Related Protein, Disrupts Olfactory, 
Gustatory, and Touch Plasticity in Caenorhabditis elegans. J Neurosci. 32: 10156-69. 
 
Frokjaer-Jensen, C, Davis, MW, Hopkins, CE, Newman, BJ, Thummel, JM, 
Olesen SP, Grunnet M, and Jorgensen EM (2008) Single-copy insertion of 
transgenes in Caenorhabditis elegans. Nat Genet 40: 1375-83. 
 
Ghosal, K, Vogt, DL, Liang, M, Shen, Y, Lamb, BT, and Pimplikar SW (2009) 
Alzheimer’s disease-like pathological features in transgenic mice expressing the APP 
intracellular domain. Proc Natl Acad Sci U S A. 106: 18367-72. 
 
Götz J, Schonrock, N, Vissel, B, and Ittner, LM (2009) Alzheimer's disease selective 
vulnerability and modeling in transgenic mice. J Alzheimers Dis.18: 243-51. 
 
Guo, X, Harada, C, Namekata, K, Matsuzawa, A, Camps, M, Ji, H, Swinnen, D, 
Jorand-Lebrun, C, Muzerelle, M, Vitte, PA, Rückle, T, Kimura, A, Kohyama, K, 
Matsumoto, Y, Ichijo, H, Harada, T (2010) Regulation of the severity of 
neuroinflammation and demyelination by TLR-ASK1-p38 pathway. EMBO Mol Med. 2: 
504-15. 
 
Huang, Y and Mucke, L (2012) Alzheimer mechanisms and therapeutic strategies. 
Cell 148: 1204-22. 
 
Hebert, LE, Scherr, PA, Bienias, JL, Bennett, DA, and Evans DA (2003) 
Alzheimer’s disease in the U.S. population: Prevalance estimates using the 2000 
census. Archives of Neurology 60: 1119-22. 
 
Hoeppner, DJ, Hengartner, MO, and Schnabel, R (2001) Engulfment genes 
cooperate with ced-3 to promote cell death in C. elegans. Nature. 412: 202-6. 
 78 
Holmes, C, Boche, D, Wilkinson, D, Yadegarfar, G, Hopkins, V, Bayer, A, Jones, 
RW, Bullock, R, Love, S, Neal, JW, Zotova, E, and Nicoll, JA (2008) Long-term 
effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, 
placebo-controlled phase I trial. Lancet 372: 216-23. 
 
Honjo, K, van Reekum, R, Verhoeff, NP (2009) Alzheimer's disease and infection: do 
infectious agents contribute to progression of Alzheimer's disease? Alzheimers Dement. 
5:  348-60. 
 
Hornsten, A, Lieberthal, J, Fadia, S, Malins, R, Ha, L, Xu, X, Daigle, I, Markowitz, 
M, O’Connor, G, Plasterk, R, and Li C (2007) APL-1, a Caenorhabditis elegans 
protein related to the human beta-ayloid precursor protein, is essential for viability. Proc 
Natl Acad Sci USA. 104: 1971-6. 
 
Iqbal, K, and Grundke-Iqbal, I (2011) Opportunities and challenges in developing 
Alzheimer disease therapeutics. Acta Neuropathol 122: 543-9. 
 
Jonsson, T, Atwal, JK, Steinberg, S, Snaedal, J, Jonsson, PV, Bjornsson, S, 
Stefansson, H, Sulem, P, Gudbjartsson, D, Maloney, J, Hoyte, K, Gustafson, A, Liu, 
Y, Lu, Y, Bhangale, T, Graham, RR, Huttenlocher, J, Bjornsdottir, G, Andreassen, 
OA, Jönsson, EG, Palotie, A, Behrens, TW, Magnusson, OT, Kong, A, 
Thorsteinsdottir, U, Watts, RJ, and Stefansson, K (2012) A mutation in APP protects 
against Alzheimer's disease and age-related cognitive decline. Nature. 488: 96-9. 
 
Kim, J, Basak, JM, and Holtzman, DM (2009). The role of apolipoprotein E in 
Alzheimer's disease. Neuron 63: 287-303. 
 
Kratsios, P, Stolfi, A, Levine, M, and Hobert O (2011) Coordinated regulation of 
cholinergic motor neuron traits through a conserved terminal selector gene. Nat 
Neurosci 15: 205-14. 
 
Krstic, D, Madhusudan, A, Doehner, J, Vogel, P, Notter, T, Imhof, C, Manalastas, 
A, Hilfiker, M, Pfister, S, Schwerdel, C, Riether, C, Meyer, U, and Knuesel, I (2012) 
Systemic immune challenges trigger and drive Alzheimer-like neuropathology in mice. J 
Neuroinflammation 9: 151. 
 
Krüger, E, and Kloetzel, PM (2012) Immunoproteasomes at the interface of innate and 
adaptive immune responses: two faces of one enzyme. Curr Opin Immunol. 24: 77-83. 
 
Li, Y, Mu, Y, and Gage, FH (2009) Development of neural circuits in the adult 
hippocampus Curr Top Dev Biol. 87: 149-74. 
 
Link, CD, Taft, A, Kapulkin, V, Duke, K, Kim, S, Fei, Q, Wood, DE and Sahagan, 
 79 
BG (2003) Gene expression analysis in transgenic Caenorhabditis elegans 
Alzheimer’s disease model Neurolbiol Aging 24: 397-413. 
 
Liu, L, Drouet, V, Wu, JW, Witter, MP, Small, SA, Clelland, C, and Duff, K (2012) 
Trans-synaptic spread of tau pathology in vivo. PLoS One 7: e31302. 
 
Matsuzawa, A, Saegusa, K, Noguchi, T, Sadamitsu, C, Nishitoh, H, Nagai, S, 
Koyasu, S, Matsumoto, K, Takeda, K, and Ichijo, H (2005) ROS-dependent activation 
of the TRAF6-ASK1-p38 pathway is selectively required for TLR4-mediated innate 
immunity Nat Immunol. 6: 587-92. 
 
Meyer, U, Nyffeler, M, Yee, BK, Knuesel, I, and Feldon, J(2008) Adult brain and 
behavioral pathological markers of prenatal immune challenge during early/middle and 
late fetal development in mice Brain Behav Immun. 22: 469-86 
. 
Nath, S, Agholme, L, Kurudenkandy, FR, Granseth, B, Marcusson, J, and Hallbeck, 
M (2012) Spreading of neurodegenerative pathology via neuron-to-neuron transmission 
of β-amyloid J Neurosci. 32: 8767-77. 
 
Neve, R, Finch, E, and Dawes, L (1988) Expression of the Alzheimer amyloid 
precursor gene transcripts in the human brain Neuron 1: 669-77. 
 
Perry, EK, Perry, RH, Blessed, G, and Tomlinson BE (1977) Necropsy evidence of 
central cholinergic deficits in senile dementia Lancet 1: 189. 
 
Park, BJ, Lee, DG, Yu, JR, Jung, SK, Choi K, Lee, J, Kim, YS, Lee, JL, 
Kwon, JY, Singson, A, Song, WK, Eom, SH, Park, CS, and Kim DH 
(2001) Calreticulin, a calcium-binding molecular chaperone, is required for stress 
response and fertility in Caenorhabditis elegans Mol Biol Cell. 12: 2835-45. 
 
Pieper, AA, Xie, S, Capota, E, Estill, SJ, Zhong, J, Long, JM, Becker, GL, 
Huntington, P, Goldman, SE, Shen, CH, Capota, M, Britt, JK, Kotti, T, Ure, K, 
Brat, DJ, Williams, NS, MacMillan, KS, Naidoo, J, Melito, L, Hsieh, J, De 
Brabander, J, Ready, JM, and McKnight, SL (2010) Discovery of a proneurogenic, 
neuroprotective chemical Cell 142: 39-51. 
 
Potts, MB, Wang, DP, and Cameron, S (2009) Trithorax, Hox, and TALE-class 
homeodomain proteins ensure cell survival through repression of the BH3-only gene 
egl-1 Dev Biol. 329: 374-85. 
 
Prasher, VP, Farrer, MJ, Kessling, AM, Fisher, EM, West, RJ, Barber, PC, and 
Butler, AC (1998) Molecular mapping of Alzheimer-type dementia in Down’s 
syndrome Ann Neurol. 43: 380-3. 
 80 
Pukkila-Worley, R, Ausubel, FM (2012) Immune defense mechanisms in the 
Caenorhabditis elegans intestinal epithelium Curr Opin Immunol. 24: 3-9. 
 
Putcha, GV, and Johnson, EM Jr. (2004) Men are but worms: neuronal cell death in 
C. elegans and vertebrates Cell Death Differ. 11: 38-48. 
 
Reddien, PW, Cameron, S, and Horvitz, HR (2001) Phagocytosis promotes 
programmed cell death in C. elegans Nature 412: 198-202. 
 
Rezai-Zadeh, K, Gate, D, Gowing, G, and Town, T (2011) How to get from here to 
there: macrophage recruitment in Alzheimer's disease Curr Alzheimer Res. 8: 156-63. 
 
Rivest, S (2009) Regulation of innate immune responses in the brain Nat Rev 
Immunol. 9: 429-39. 
 
Rodríguez, JJ, and Verkhratsky, A (2011) Neurogenesis in Alzheimer's disease J 
Anat. 219: 78-89. 
 
Sagasti, A, Hisamoto, N, Hyodo, J, Tanaka-Hino, M, Matsumoto, K, Bargmann, CI 
(2001) The CaMKII UNC-43 activates the MAPKKK NSY-1 to execute a lateral 
signaling decision required for asymmetric olfactory neuron fates Cell 105: 221-32. 
 
Salehi, A, Delcroix, JD, Belichenko, PV, Zhan, K, Wu, C, Valletta, JS, Takimoto- 
Kimura, R, Kleschevnikov, A.M, Sambamurti, K, Chung, P.P, Xia, W, Villar, A, 
Campbell, WA, Kulnane, LS, Nixon, RA, Lamb, BT, Epstein, CJ, Stokin, GB, 
Goldstein, LS, and Mobley, WC (2006) Increased App expression in a mouse model 
of Down's syndrome disrupt NGF transport and causes cholinergic neuron 
degeneration Neuron 51: 29-42. 
 
Saxena, S and Caroni, P (2011) Selective vulnerability in neurodegenerative 
diseases: from stressor thresholds to degeneration Neuron 71: 35-48. 
 
Schreiber, MA, and McIntire, SL (2011) A Caenorhabditis elegans p38 MAP kinase 
pathway mutant protects from dopamine, methamphetamine, and MDMA toxicity 
Neurosci Lett. 498: 99-103. 
 
Sierra, A, Encinas, JM, Deudero, JJ, Chancey, JH, Enikolopov, G, Overstreet- 
Wadiche, LS, Tsirka, SE, and Maletic-Savatic M (2010) Microglia shape adult 
hippocampal neurogenesis through apoptosis-coupled phagocytosis Cell Stem Cell 7: 
483-95. 
 
Silva, MC, Fox, S, Beam, M, Thakkar, H, Amaral, MD, and Morimoto RI (2011) A 
genetic screening strategy identifies novel regulators of the proteostasis network PLoS 
 81 
Genet. 7: e1002438. 
 
Simon, AM, Schiapparelli, L, Salazar-Colocho, P, Cuadrado-Trejedor, M, Escribano, 
L, Lopez de Maturana, R, Del Rio, J, Perez-Mediavilla, A, and Frechilla, D 
(2009) Overexpression of wild-type human APP in mice causes cognitive deficits and 
pathological features unrelated to Abeta levels Neurobiol Dis. 33: 369-78. 
 
Small, SA, and Duff K (2008) Linking Abeta and tau in late-onset Alzheimer’s disease: 
a dual pathway hypothesis Neuron 60: 534-42. 
 
Steele, JW, Lachenmayer, ML, Ju, S, Stock, A, Liken, J, Kim, SH, Delgado, LM, 
Alfaro, IE, Bernales, S, Verdile, G, Bharadwaj, P, Gupta, V, Barr, R, Friss, A, 
Dolios, G, Wang, R, Ringe, D, Fraser, P, Westaway, D, St George-Hyslop, PH, 
Szabo, P, Relkin, NR, Buxbaum, JD, Glabe, CG, Protter, AA, Martins, RN, 
Ehrlich, ME, Petsko, GA, Yue, Z, and Gandy, S (2012) Latrepirdine improves 
cognition and arrests progression of neuropathology in an Alzheimer's mouse model 
Mol Psychiatry. 10.1038/mp.2012.106. 
 
Sulston, JE (1983) Neuronal cell lineages in the nematode Caenorhabditis elegans 
Cold Spring Harb Symp Quant Biol. 48: 443-52. 
 
Tatar, M (2010) Reproductive Aging in Invertebrate Genetic Models Ann N Y Acad 
Sci. 1204: 149-55. 
 
Vidal-Gadea, A, Topper, S, Young, L, Crisp, A, Kressin, L, Elbel, E, Maples, T, 
Brauner, M, Erbguth, K, Axelrod, A, Gottschalk, A, Siegel, D, Pierce-Shimomura, JT 
(2011) Caenorhabditis elegans selects distinct crawling and swimming gaits via 
dopamine and serotonin Proc Natl Acad Sci U S A. 108: 17504-9. 
 
Wentzell, J, and Kretzchmar, D (2010) Alzheimer’s disease and taupathy studies in 
flies and worms Neurobiol Dis. 40: 21-8. 
 
Wes, PD and Bargmann, CI (2001) C. elegans odour discrimination requires 
asymmetric diversity in olfactory neurons Nature 410: 698-701. 
 
White, JG, Southgate, E, Thomson, JN, and Brenner, S (1986) The structure of the 
nervous system of the nematode Caenorhabditis elegans Philosophical Transactions 
of the Royal Society of London B. Biological Sciences 314: 1-340. 
 
Youngman, MJ, Rogers, ZN, and Kim, DH A decline in p38 MAPK signaling 
underlies immunosenescence in Caenorhabditis elegans PLoS Genet. 7: e1002082. 
 




 Zhang, M, Chung, SH, Fang-Yen, C, Craig, C, Kerr, RA, Suzuki, H, Samuel, AD, 
Mazur, E, and Schafer WR (2008) A self-regulating feed-forward circuit controlling C. 
elegans egg-laying behavior Curr Biol 18: 1445-55. 
 
Zhang H, Ma Q, Zhang YW, and Xu H (2012) Proteolytic processing of Alzheimer’s 
β-amyloid precursor protein J Neurochem. 120: 9-21. 
 
Zigman, WB and Lott IT (2007) Alzheimer’s disease in Down syndrome: Neurobiology 





 Ashley Aaron Crisp was born in Belvidere, Illinois on April 8
th
, 1985.  She 
obtained a Bachelor of Science degree in Biology from Northern Illinois University in 
2007.  She also minored in Chemistry and became a certified secondary education 
teacher.  She then moved on to get a Doctor of Philosophy in Cellular Molecular Biology 
from the University of Texas at Austin in 2013, under the advisory of Dr. Jon Pierce-
Shimomura. 
 Ashley has several given several presentations and produced publications during 
her time in graduate school.  They include the following:  “Using C. elegans to 
understand Down syndrome.”  Institute for Neuroscience 14
th
 Annual Symposium, 
Austin TX, USA, 2010; “Age-related cholinergic neurodegeneration by overexpression 
of apl-1  in  C. elegans.” Neuronal development, synaptic function & behavior C. elegans 
topic meeting, Madison WI, USA, 2010; “A C. elegans model for Down syndrome.”  
Society for Neurocience Annual Symposium, San Diego CA, USA, 2010; “Serotinergic 
blockade prevents age-related neurodegeneration in a C. elegans model of AD.”  Institue 
for Neuroscience 15
th
 Annual Symposium, Austin TX, USA, 2011; “Serotinergic 
blockade prevents age-related neurodegeneration in a C. elegans model of AD.” 18
th
 
international C. elegans meeting, Los Angeles CA, USA, 2011;  “Serotinergic blockade 
prevents age-related neurodegeneration in a C. elegans model of AD.”  Alzheimer’s 
Association International Conference, Paris, France, 2011;  Vidal-Gadea et al. C. 
elegans selects distinct crawling and swimming gaits via dopamine and serotonin. Proc 
Natl Acad Sci U S A. 108, 17504-9 (2011);   “Induction and prevention of patterned 
degeneration by Amyloid Precursor Protein.” Alzheimer’s Association International 
Conference, Vancouver BC, Canada, 2012;  “Induction and prevention of patterned 
degeneration by Amyloid Precursor Protein.” Society for Neuroscience Annual 
 84 
Symposium, New Orleans LA, USA, 2012;  “Studying mechanism and medicine of 
Alzheimer’s disease with worms.” Center for Learning and Memory 6
th
 Annual Retreat, 
Austin TX, USA, 2012;  Crisp A., Pierce-Shimomura J. Induction and prevention of 
patterned neurodegeneration in Alzheimer’s Disease (in submission). 
 
 This publication was typed by the author.  She can be reached by permanent email 
at ashleyacrisp@gmail.com. 
 
